Hubbry Logo
SepsisSepsisMain
Open search
Sepsis
Community hub
Sepsis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Sepsis
Sepsis
from Wikipedia

sepsis
skin blotching and inflammation caused by sepsis
Pronunciation
SpecialtyInfectious disease, critical care medicine, emergency medicine
Symptoms
Complications
Usual onsetmay be rapid (less than three hours) or prolonged (several days)
CausesImmune response triggered by an infection[2][3]
Risk factors[1]
Diagnostic methodsystemic inflammatory response syndrome (SIRS),[2] qSOFA[4]
Preventioninfluenza vaccination, vaccines, pneumonia vaccination
Treatmentintravenous fluids, antimicrobials, vasopressors[1][5]
Prognosismortality: sepsis ~30%, severe sepsis ~50%, septic shock ~80%. The mortality may be lower if treated aggressively and early, depending on the organism and disease, the patient's previous health, and the abilities of the treatment location and its staff.
FrequencyIn 2017, there were 48.9 million cases and 11 million sepsis-related deaths worldwide (according to WHO)

Sepsis is a potentially life-threatening condition that arises when the body's dysregulated response to infection causes injury to its own tissues and organs.[4][6]

This initial stage of sepsis is followed by dysregulation of the immune system.[7] Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion.[1] There may also be symptoms related to a specific infection, such as a cough with pneumonia, or painful urination with a kidney infection.[2] The very young, old, and people with a weakened immune system may not have any symptoms specific to their infection, and their body temperature may be low or normal instead of constituting a fever.[2] Severe sepsis may cause organ dysfunction and significantly reduced blood flow.[8] The presence of low blood pressure, high blood lactate, or low urine output may suggest poor blood flow.[8] Septic shock is low blood pressure due to sepsis that does not improve after fluid replacement or requires medications to raise the blood pressure.[8][9]

Sepsis is caused by many organisms including bacteria, viruses, and fungi.[10] Gram negative and gram positive bacteria are the most common causes of sepsis. Viral pathogens and diarrheal illnesses are common causes in children.[9] In 60–70% of cases an infectious pathogen is found.[9] Common locations for the primary infection include the lungs, brain, urinary tract, skin, and abdominal organs.[2] Risk factors include being very young or old, a weakened immune system from conditions such as cancer or diabetes, major trauma, and burns.[1] A shortened sequential organ failure assessment score (SOFA score), known as the quick SOFA score (qSOFA), has replaced the SIRS system of diagnosis.[4] qSOFA criteria for sepsis include at least two of the following three: increased breathing rate, change in the level of consciousness, and low blood pressure.[4] Sepsis guidelines recommend obtaining blood cultures before starting antibiotics; however, the diagnosis does not require the blood to be infected.[2] Medical imaging is helpful when looking for the possible location of the infection.[8] Other potential causes of similar signs and symptoms include anaphylaxis, adrenal insufficiency, low blood volume, heart failure, and pulmonary embolism.[2]

Sepsis requires immediate treatment with intravenous fluids and antimicrobial medications.[1][5] Ongoing care and stabilization often continues in an intensive care unit.[1] If an adequate trial of fluid replacement is not enough to maintain blood pressure, then the use of medications that raise blood pressure becomes necessary.[1] Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively.[1] A central venous catheter and arterial line may be placed for access to the bloodstream and to guide treatment.[8] Other helpful measurements include cardiac output and superior vena cava oxygen saturation.[8] People with sepsis need preventive measures for deep vein thrombosis, stress ulcers, and pressure ulcers unless other conditions prevent such interventions.[8] Some people might benefit from tight control of blood sugar levels with insulin.[8] The use of corticosteroids is controversial, with some reviews finding benefit,[11][12] others not.[13]

A person's age, immune system function, the virulence of the pathogen causing infection, the amount of microorganisms in the body causing infection (pathogen burden) all affect the incidence, severity and prognosis of sepsis.[9][14] The risk of death from sepsis is as high as 30%, while for severe sepsis it is as high as 50%, and the risk of death from septic shock is 80%.[15][16][14] Sepsis affected about 49 million people in 2017, with 11 million deaths (1 in 5 deaths worldwide).[17] In the developed world, approximately 0.2 to 3 people per 1000 are affected by sepsis yearly.[14][18] Rates of disease have been increasing.[8] 85% of cases occurred in low or middle income countries with 40% of cases worldwide occurring in Sub-Saharan Africa.[9] Some data indicate that sepsis is more common among men than women;[2] however, other data show a greater prevalence of the disease among women.[17]

Video summary (script)

Signs and symptoms

[edit]

In addition to symptoms related to the actual cause, people with sepsis may have a fever, low body temperature, rapid breathing, a fast heart rate, confusion, and edema.[19] Early signs include a rapid heart rate, decreased urination, and high blood sugar. Signs of established sepsis include confusion, metabolic acidosis (which may be accompanied by a faster breathing rate that leads to respiratory alkalosis), low blood pressure due to decreased systemic vascular resistance, higher cardiac output, and disorders in blood-clotting that may lead to organ failure.[20] Fever is the most common presenting symptom in sepsis, but fever may be absent in some people, such as the elderly or those who are immunocompromised.[21]

The drop in blood pressure seen in sepsis can cause lightheadedness and is part of the criteria for septic shock.[22]

Oxidative stress is observed in septic shock, with circulating levels of copper and vitamin C being decreased.[23]

Diastolic blood pressure falls during the early stages of sepsis, causing a widening/increasing of pulse pressure, which is the difference between the systolic and diastolic blood pressures. If sepsis becomes severe and hemodynamic compromise advances, the systolic pressure also decreases, causing a narrowing/decreasing of pulse pressure.[24] A pulse pressure of over 70 mmHg in patients with sepsis is correlated with an increased chance of survival.[25] A widened pulse pressure is also correlated with an increased chance that someone with sepsis will benefit from and respond to IV fluids.[25]

Cause

[edit]
Patient of an intensive care unit of a German hospital (2015) with severe sepsis caused by a chain reaction of incidental negative events after a prior surgery of the abdomen. After an emergency surgery, he received antibiotics, parenteral nutrition, and pain killers via automated injection employing infusion pumps (background right). Hemodialysis via the machine on the left became necessary due to kidney malfunction and multiple organ dysfunction syndrome. After three months in the hospital, the patient recovered within a month and has since then fully recovered (as of 2023).

Infections leading to sepsis are usually bacterial but may be fungal, parasitic, or viral.[26] Gram-positive bacteria were the primary cause of sepsis before the introduction of antibiotics in the 1950s. After the introduction of antibiotics, gram-negative bacteria became the predominant cause of sepsis from the 1960s to the 1980s.[27] After the 1980s, gram-positive bacteria, most commonly staphylococci, are thought to cause more than 50% of cases of sepsis.[18][28] Other commonly implicated bacteria include Streptococcus pyogenes, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella species.[29] Fungal sepsis accounts for approximately 5% of severe sepsis and septic shock cases; the most common cause of fungal sepsis is an infection by Candida species of yeast,[30] a frequent hospital-acquired infection. The most common causes for parasitic sepsis are Plasmodium (which leads to malaria), Schistosoma and Echinococcus.

The most common sites of infection resulting in severe sepsis are the lungs, the abdomen, and the urinary tract.[26] 40–60% of infections causing sepsis originate in the lungs, 15–30% are abdominal infections, and 15–30% are bladder, kidney, skin or soft tissue infections.[9] But the site of infection, as well as the causative infectious pathogen vary depending on geographic location and region.[9]

Pathophysiology

[edit]

Sepsis is caused by a combination of factors related to the particular invading pathogen(s) and the status of the immune system of the host.[31] The early phase of sepsis, characterized by excessive inflammation (sometimes resulting in a cytokine storm), may be followed by a prolonged period of decreased functioning of the immune system.[32][7] Either of these phases may prove fatal. On the other hand, systemic inflammatory response syndrome (SIRS) occurs in people without the presence of infection, for example, in those with burns, polytrauma, or the initial state in pancreatitis and chemical pneumonitis. However, sepsis also causes a similar response to SIRS.[33]

Platelets have a potentially key role in immune modulation during sepsis.[34] Systemic inflammation, endothelial injury, and dysregulated coagulation activate platelets in the early phases of the condition.[34] These activated platelets interact with leukocytes and endothelial cells, amplifying both inflammatory and thrombotic responses.[34] This interaction contributes to microvascular thrombosis and progression to multiple organ dysfunction syndrome.[34]

Microbial factors

[edit]

Bacterial virulence factors, such as glycocalyx and various adhesins, allow colonization, immune evasion, and establishment of disease in the host.[31] Sepsis caused by gram-negative bacteria is thought to be largely due to a response by the host to the lipid A component of lipopolysaccharide, also called endotoxin.[35][36] Sepsis caused by gram-positive bacteria may result from an immunological response to cell wall lipoteichoic acid.[37] Bacterial exotoxins that act as superantigens also may cause sepsis.[31] Superantigens simultaneously bind major histocompatibility complex and T-cell receptors in the absence of antigen presentation. This forced receptor interaction induces the production of pro-inflammatory chemical signals (cytokines) by T-cells.[31]

There are several microbial factors that may cause the typical septic inflammatory cascade. An invading pathogen is recognized by its pathogen-associated molecular patterns (PAMPs). Examples of PAMPs include lipopolysaccharides and flagellin in gram-negative bacteria, muramyl dipeptide in the peptidoglycan of the gram-positive bacterial cell wall, and CpG bacterial DNA. These PAMPs are recognized by the pattern recognition receptors (PRRs) of the innate immune system, which may be membrane-bound or cytosolic.[38] There are four families of PRRs: the toll-like receptors, the C-type lectin receptors, the NOD-like receptors, and the RIG-I-like receptors. Invariably, the association of a PAMP and a PRR will cause a series of intracellular signalling cascades. Consequently, transcription factors such as nuclear factor-kappa B and activator protein-1 will up-regulate the expression of pro-inflammatory and anti-inflammatory cytokines.[39]

Other immunological responses related to microbial infections, such as NETs, can also play a role or be observed in sepsis. NET formation only occurs via neutrophil cell death, which occurs during microbial infections. Neutrophil extracellular traps, called NETs, eliminate bacteria from the blood flow. These compounds are part of the innate immune system, which is activated initially during infections.[40]

Host factors

[edit]

Upon detection of microbial antigens, the host systemic immune system is activated. Immune cells not only recognise pathogen-associated molecular patterns but also damage-associated molecular patterns from damaged tissues. An uncontrolled immune response is then activated because leukocytes are not recruited to the specific site of infection, but instead, they are recruited all over the body. Then, an immunosuppression state ensues when the proinflammatory T helper cell 1 (TH1) is shifted to TH2,[41] mediated by interleukin 10, which is known as "compensatory anti-inflammatory response syndrome".[27] The apoptosis (cell death) of lymphocytes further worsens the immunosuppression. Neutrophils, monocytes, macrophages, dendritic cells, CD4+ T cells, and B cells all undergo apoptosis, whereas regulatory T cells are more apoptosis-resistant.[7] Subsequently, multiple organ failure ensues because tissues are unable to use oxygen efficiently due to inhibition of cytochrome c oxidase, possibly as part of a "cell hibernation" mechanism, to conserve oxygen.[41]

Inflammatory responses cause multiple organ dysfunction syndrome through various mechanisms as described below. Increased permeability of the lung vessels causes leaking of fluids into alveoli, which results in pulmonary edema and acute respiratory distress syndrome (ARDS). Impaired utilization of oxygen in the liver impairs bile salt transport, causing jaundice (yellowish discoloration of the skin). In kidneys, inadequate oxygenation results in tubular epithelial cell injury (of the cells lining the kidney tubules), and thus causes acute kidney injury (AKI). Meanwhile, in the heart, impaired calcium transport and low production of adenosine triphosphate (ATP) can cause myocardial depression, reducing cardiac contractility and causing heart failure. In the gastrointestinal tract, increased permeability of the mucosa alters the microflora, causing mucosal bleeding and paralytic ileus. In the central nervous system, direct damage of the brain cells and disturbances of neurotransmissions causes altered mental status.[42] Cytokines such as tumor necrosis factor, interleukin 1, and interleukin 6 may activate procoagulation factors in the cells lining blood vessels, leading to endothelial damage. The damaged endothelial surface inhibits anticoagulant properties as well as increases antifibrinolysis, which may lead to intravascular clotting, the formation of blood clots in small blood vessels, and multiple organ failure.[43]

The low blood pressure seen in those with sepsis is the result of various processes, including excessive production of chemicals that dilate blood vessels such as nitric oxide, a deficiency of chemicals that constrict blood vessels such as vasopressin, and activation of ATP-sensitive potassium channels.[44] In those with severe sepsis and septic shock, this sequence of events leads to a type of circulatory shock known as distributive shock.[45]

Diagnosis

[edit]

Early diagnosis is necessary to properly manage sepsis, as the initiation of rapid therapy is key to reducing deaths from severe sepsis.[8] Some hospitals use alerts generated from electronic health records to bring attention to potential cases as early as possible.[46]

Blood culture bottles: orange cap for anaerobes, green cap for aerobes, and yellow cap for blood samples from children[47]

Within the first three hours of suspected sepsis, diagnostic studies should include white blood cell counts, measuring serum lactate, and obtaining appropriate cultures before starting antibiotics, so long as this does not delay their use by more than 45 minutes.[8] To identify the causative organism(s), at least two sets of blood cultures using bottles with media for aerobic and anaerobic organisms are necessary. At least one should be drawn through the skin and one through each vascular access device (such as an IV catheter) that has been in place for more than 48 hours.[8] Bacteria are present in the blood in only about 30% of cases.[48] Another possible method of detection is by polymerase chain reaction. If other sources of infection are suspected, cultures of these sources, such as urine, cerebrospinal fluid, wounds, or respiratory secretions, also should be obtained, as long as this does not delay the use of antibiotics.[8]

Within six hours, if blood pressure remains low despite initial fluid resuscitation of 30 mL/kg, or if initial lactate is ≥ four mmol/L (36 mg/dL), central venous pressure and central venous oxygen saturation should be measured.[8] Lactate should be re-measured if the initial lactate was elevated.[8] Evidence for point of care lactate measurement over usual methods of measurement, however, is poor.[49]

Within twelve hours, it is essential to diagnose or exclude any source of infection that would require emergent source control, such as a necrotizing soft tissue infection, an infection causing inflammation of the abdominal cavity lining, an infection of the bile duct, or an intestinal infarction.[8] A pierced internal organ (free air on an abdominal X-ray or CT scan), an abnormal chest X-ray consistent with pneumonia (with focal opacification), or petechiae, purpura, or purpura fulminans may indicate the presence of an infection.[citation needed]

Definitions

[edit]
Systemic inflammatory response syndrome[50]
Finding Value
Temperature <36 °C (96.8 °F) or >38 °C (100.4 °F)
Heart rate >90/min
Respiratory rate >20/min or PaCO2<32 mmHg (4.3 kPa)
WBC <4x109/L (<4000/mm3), >12x109/L (>12,000/mm3), or ≥10% bands
Sepsis Steps. Training tool for teaching the progression of sepsis stages

Previously, SIRS criteria had been used to define sepsis. If the SIRS criteria are negative, it is very unlikely the person has sepsis; if it is positive, there is just a moderate probability that the person has sepsis. According to SIRS, there were different levels of sepsis: sepsis, severe sepsis, and septic shock.[33] The definition of SIRS is shown below:

In 2016, a new consensus was reached to replace screening by systemic inflammatory response syndrome (SIRS) with the sequential organ failure assessment (SOFA score) and the abbreviated version (qSOFA).[4] The three criteria for the qSOFA score include a respiratory rate greater than or equal to 22 breaths per minute, systolic blood pressure 100 mmHg or less, and altered mental status.[4] Sepsis is suspected when 2 of the qSOFA criteria are met.[4] The SOFA score was intended to be used in the intensive care unit (ICU) where it is administered upon admission to the ICU and then repeated every 48 hours, whereas the qSOFA could be used outside the ICU.[21] Some advantages of the qSOFA score are that it can be administered quickly and does not require labs.[21] However, the American College of Chest Physicians (CHEST) raised concerns that qSOFA and SOFA criteria may lead to delayed diagnosis of serious infection, leading to delayed treatment.[52] Although SIRS criteria can be too sensitive and not specific enough in identifying sepsis, SOFA also has its limitations and is not intended to replace the SIRS definition.[53] qSOFA has also been found to be poorly sensitive though decently specific for the risk of death with SIRS possibly better for screening. NOTE - Surviving Sepsis Campaign 2021 Guidelines recommend "against using qSOFA compared with SIRS, NEWS, or MEWS as a single screening tool for sepsis or septic shock".[54]

End-organ dysfunction

[edit]

Examples of end-organ dysfunction include the following:[55]

More specific definitions of end-organ dysfunction exist for SIRS in pediatrics.[56]

Consensus definitions, however, continue to evolve, with the latest expanding the list of signs and symptoms of sepsis to reflect clinical bedside experience.[19]

Biomarkers

[edit]

Biomarkers can help with diagnosis because they can point to the presence or severity of sepsis, although their exact role in the management of sepsis remains undefined.[57] A 2013 review concluded moderate-quality evidence exists to support the use of the procalcitonin level as a method to distinguish sepsis from non-infectious causes of SIRS.[48] The same review found the sensitivity of the test to be 77% and the specificity to be 79%. The authors suggested that procalcitonin may serve as a helpful diagnostic marker for sepsis, but cautioned that its level alone does not definitively make the diagnosis.[48] More current literature recommends utilizing the PCT to direct antibiotic therapy for improved antibiotic stewardship and better patient outcomes.[58]

A 2012 systematic review found that soluble urokinase-type plasminogen activator receptor (SuPAR) is a nonspecific marker of inflammation and does not accurately diagnose sepsis.[59] This same review concluded, however, that SuPAR has prognostic value, as higher SuPAR levels are associated with an increased rate of death in those with sepsis.[59] Serial measurement of lactate levels (approximately every 4 to 6 hours) may guide treatment and is associated with lower mortality in sepsis.[21]

Differential diagnosis

[edit]

The differential diagnosis for sepsis is broad and has to examine (to exclude) the non-infectious conditions that may cause the systemic signs of SIRS: alcohol withdrawal, acute pancreatitis, burns, pulmonary embolism, thyrotoxicosis, anaphylaxis, adrenal insufficiency, and neurogenic shock.[20][60] Hyperinflammatory syndromes such as hemophagocytic lymphohistiocytosis (HLH) may have similar symptoms and are on the differential diagnosis.[61]

Neonatal sepsis

[edit]

In common clinical usage, neonatal sepsis refers to a bacterial blood stream infection in the first month of life, such as meningitis, pneumonia, pyelonephritis, or gastroenteritis,[62] but neonatal sepsis also may be due to infection with fungi, viruses, or parasites.[62] Criteria with regard to hemodynamic compromise or respiratory failure are not useful because they present too late for intervention.[63]

Treatment

[edit]
Intravenous fluids being given

Sepsis requires immediate treatment in a hospital as it can quickly worsen. Current professional recommendations include several actions ("bundles") to be followed as soon as possible after diagnosis. Within the first three hours, someone with sepsis should have received antibiotics and intravenous fluids if there is evidence of either low blood pressure or other evidence for inadequate blood supply to organs (as evidenced by a raised level of lactate); blood cultures should also be obtained within this period. After six hours, the blood pressure should be adequate, close monitoring of blood pressure and blood supply to organs should be in place, and the lactate should be measured again if initially it was raised.[8] A related bundle, the "Sepsis Six", is in widespread use in the United Kingdom; this requires the administration of antibiotics within an hour of recognition, blood cultures, lactate, and hemoglobin determination, urine output monitoring, high-flow oxygen, and intravenous fluids.[64][65]

Apart from the timely administration of fluids and antibiotics, the management of sepsis also involves surgical drainage of infected fluid collections and appropriate support for organ dysfunction. This may include hemodialysis in kidney failure, mechanical ventilation in lung dysfunction, transfusion of blood products, and drug and fluid therapy for circulatory failure. Ensuring adequate nutrition—preferably by enteral feeding, but if necessary, by parenteral nutrition—is important during prolonged illness.[8] Medication to prevent deep vein thrombosis and gastric ulcers also may be used.[8]

Antibiotics

[edit]

Two sets of blood cultures (aerobic and anaerobic) are recommended without delaying the initiation of antibiotics. Cultures from other sites such as respiratory secretions, urine, wounds, cerebrospinal fluid, and catheter insertion sites are recommended if infections from these sites are suspected.[5] In severe sepsis and septic shock, broad-spectrum antibiotics (usually two, a β-lactam antibiotic with broad coverage, or broad-spectrum carbapenem combined with fluoroquinolones, macrolides, or aminoglycosides) are recommended. The choice of antibiotics is important in determining the survival of the person.[45][5] Some recommend they be given within one hour of making the diagnosis, stating that for every hour of delay in the administration of antibiotics, there is an associated 6% rise in mortality.[51][45] Others did not find a benefit with early administration.[66]

Several factors determine the most appropriate choice for the initial antibiotic regimen. These factors include local patterns of bacterial sensitivity to antibiotics, whether the infection is thought to be a hospital or community-acquired infection, and which organ systems are thought to be infected.[45][21] Antibiotic regimens should be reassessed daily and narrowed if appropriate. Treatment duration is typically 7–10 days with the type of antibiotic used directed by the results of cultures. If the culture result is negative, antibiotics should be de-escalated according to the person's clinical response or stopped altogether if an infection is not present to decrease the chances that the person is infected with multiple drug resistance organisms. In case of people having a high risk of being infected with multiple drug resistant organisms such as Pseudomonas aeruginosa, Acinetobacter baumannii, the addition of an antibiotic specific to the organism is recommended. For methicillin-resistant Staphylococcus aureus (MRSA), vancomycin or teicoplanin is recommended. For Legionella infection, addition of macrolide or fluoroquinolone is chosen. If fungal infection is suspected, an echinocandin, such as caspofungin or micafungin, is chosen for people with severe sepsis, followed by triazole (fluconazole and itraconazole) for less ill people.[5] Prolonged antibiotic prophylaxis is not recommended in people who have SIRS without any infectious origin, such as acute pancreatitis and burns unless sepsis is suspected.[5]

Once-daily dosing of aminoglycoside is sufficient to achieve peak plasma concentration for a clinical response without kidney toxicity. Meanwhile, for antibiotics with low volume distribution (vancomycin, teicoplanin, colistin), a loading dose is required to achieve an adequate therapeutic level to fight infections. Frequent infusions of beta-lactam antibiotics without exceeding the total daily dose would help to keep the antibiotic level above minimum inhibitory concentration (MIC), thus providing a better clinical response.[5] Giving beta-lactam antibiotics continuously may be better than giving them intermittently.[67] Access to therapeutic drug monitoring is important to ensure adequate drug therapeutic level while at the same time preventing the drug from reaching a toxic level.[5]

Intravenous fluids

[edit]

The Surviving Sepsis Campaign has recommended 30 mL/kg of fluid to be given in adults in the first three hours followed by fluid titration according to blood pressure, urine output, respiratory rate, and oxygen saturation with a target mean arterial pressure (MAP) of 65 mmHg.[5] In children, an initial amount of 20 mL/kg is reasonable in shock.[68] In cases of severe sepsis and septic shock where a central venous catheter is used to measure blood pressures dynamically, fluids should be administered until the central venous pressure reaches 8–12 mmHg.[44] Once these goals are met, the central venous oxygen saturation (ScvO2), i.e., the oxygen saturation of venous blood as it returns to the heart as measured at the vena cava, is optimized.[5] If the ScvO2 is less than 70%, blood may be given to reach a hemoglobin of 10 g/dL and then inotropes are added until the ScvO2 is optimized.[31] In those with acute respiratory distress syndrome (ARDS) and sufficient tissue blood fluid, more fluids should be given carefully.[8]

Crystalloid solution is recommended as the fluid of choice for resuscitation.[5] "Balanced" crystalloid solutions such as lactated ringers (which have levels of sodium, potassium and chloride closer to a person's extracellular levels) are associated with a lower mortality as compared to normal saline solutions in the treatment of sepsis.[9] Albumin can be used if a large amount of crystalloid is required for resuscitation.[5] Crystalloid solutions shows little difference with hydroxyethyl starch in terms of risk of death.[69] Starches also carry an increased risk of acute kidney injury,[69][70] and need for blood transfusion.[71][72] Various colloid solutions (such as modified gelatin) carry no advantage over crystalloid.[69] Albumin also appears to be of no benefit over crystalloids.[73]

Blood products

[edit]

The Surviving Sepsis Campaign recommended packed red blood cells transfusion for hemoglobin levels below 70 g/L if there is no myocardial ischemia, hypoxemia, or acute bleeding.[5] In a 2014 trial, blood transfusions to keep target hemoglobin above 70 or 90 g/L did not make any difference to survival rates; meanwhile, those with a lower threshold of transfusion received fewer transfusions in total.[74] Erythropoietin is not recommended in the treatment of anemia with septic shock because it may precipitate blood clotting events. Fresh frozen plasma transfusion usually does not correct the underlying clotting abnormalities before a planned surgical procedure. However, platelet transfusion is suggested for platelet counts below (10 billion/L) without any risk of bleeding, or (20 billion/L) with a high risk of bleeding, or (50 billion/L) with active bleeding, before planned surgery or an invasive procedure.[5] IV immunoglobulin is not recommended because its beneficial effects are uncertain.[5] Monoclonal and polyclonal preparations of intravenous immunoglobulin (IVIG) do not lower the rate of death in newborns and adults with sepsis.[75] Evidence for the use of IgM-enriched polyclonal preparations of IVIG is inconsistent.[75] On the other hand, the use of antithrombin to treat disseminated intravascular coagulation is also not useful. Meanwhile, the blood purification technique (such as hemoperfusion, plasma filtration, and coupled plasma filtration adsorption) to remove inflammatory mediators and bacterial toxins from the blood also does not demonstrate any survival benefit for septic shock.[5]

Vasopressors

[edit]

If the person has been sufficiently fluid resuscitated but the mean arterial pressure is not greater than 65 mmHg, vasopressors are recommended.[5] Norepinephrine (noradrenaline) is recommended as the initial choice.[5] Delaying initiation of vasopressor therapy during septic shock is associated with increased mortality.[76]

Norepinephrine is often used as a first-line treatment for hypotensive septic shock because evidence shows that there is a relative deficiency of vasopressin when shock continues for 24 to 48 hours.[77] Norepinephrine raises blood pressure through a vasoconstriction effect, with little effect on stroke volume and heart rate.[5] In some people, the required dose of vasopressor needed to increase the mean arterial pressure can become exceedingly high, and it becomes toxic.[78] To reduce the required dose of vasopressor, epinephrine may be added.[78] Epinephrine is not often used as a first-line treatment for hypotensive shock because it reduces blood flow to the abdominal organs and increases lactate levels.[77] Vasopressin can be used in septic shock because studies have shown that there is a relative deficiency of vasopressin when shock continues for 24 to 48 hours. However, vasopressin reduces blood flow to the heart, fingers/toes, and abdominal organs, resulting in a lack of oxygen supply to these tissues.[5] Dopamine is typically not recommended. Although dopamine is useful for increasing the stroke volume of the heart, it causes more abnormal heart rhythms than norepinephrine and also has an immunosuppressive effect. Dopamine is not proven to have protective properties on the kidneys.[5] Dobutamine can also be used in hypotensive septic shock to increase cardiac output and correct blood flow to the tissues.[79] Dobutamine is not used as often as epinephrine due to its associated side effects, which include reducing blood flow to the gut.[79] Additionally, dobutamine increases the cardiac output by abnormally increasing the heart rate.[79]

Steroids

[edit]

The use of steroids in sepsis is controversial.[80] Studies do not give a clear picture as to whether and when glucocorticoids should be used.[81] The 2016 Surviving Sepsis Campaign recommends low-dose hydrocortisone only if both intravenous fluids and vasopressors are not able to adequately treat septic shock.[5] The 2021 Surviving Sepsis Campaign recommends IV corticosteroids for adults with septic shock who have an ongoing requirement for vasopressor therapy. A 2019 Cochrane (updated in 2025) review found moderate certainty evidence of benefit,[11] as did two 2019 reviews.[12][82]

During critical illness, a state of adrenal insufficiency and tissue resistance to corticosteroids may occur. This has been termed critical illness–related corticosteroid insufficiency.[83] Treatment with corticosteroids might be most beneficial in those with septic shock and early severe ARDS, whereas its role in others such as those with pancreatitis or severe pneumonia is unclear.[83] However, the exact way of determining corticosteroid insufficiency remains problematic. It should be suspected in those poorly responding to resuscitation with fluids and vasopressors. Neither ACTH stimulation testing[83] nor random cortisol levels are recommended to confirm the diagnosis.[5] The method of stopping glucocorticoid drugs is variable, and it is unclear whether they should be slowly decreased or simply abruptly stopped. However, the 2016 Surviving Sepsis Campaign recommended tapering steroids when vasopressors are no longer needed.[5]

Anesthesia

[edit]

A target tidal volume of 6 mL/kg of predicted body weight (PBW) and a plateau pressure less than 30 cm H2O is recommended for those who require ventilation due to sepsis-induced severe ARDS. High positive end expiratory pressure (PEEP) is recommended for moderate to severe ARDS in sepsis as it opens more lung units for oxygen exchange. Predicted body weight is calculated based on sex and height, and tools for this are available.[84] Recruitment maneuvers may be necessary for severe ARDS by briefly raising the transpulmonary pressure. It is recommended that the head of the bed be raised if possible to improve ventilation. However, β2 adrenergic receptor agonists are not recommended to treat ARDS because they may reduce survival rates and precipitate abnormal heart rhythms. A spontaneous breathing trial using continuous positive airway pressure (CPAP), T piece, or inspiratory pressure augmentation can help reduce the duration of ventilation. Minimizing intermittent or continuous sedation helps reduce the duration of mechanical ventilation.[5]

General anesthesia is recommended for people with sepsis who require surgical procedures to remove the infectious source. Usually, inhalational and intravenous anesthetics are used. Requirements for anesthetics may be reduced in sepsis. Inhalational anesthetics can reduce the level of proinflammatory cytokines, altering leukocyte adhesion and proliferation, inducing apoptosis (cell death) of the lymphocytes, possibly with a toxic effect on mitochondrial function.[41] Although etomidate has a minimal effect on the cardiovascular system, it is often not recommended as a medication to help with intubation in this situation due to concerns it may lead to poor adrenal function and an increased risk of death.[85][86] The small amount of evidence there is, however, has not found a change in the risk of death with etomidate.[87]

Paralytic agents are not suggested for use in sepsis cases in the absence of ARDS, as a growing body of evidence points to reduced durations of mechanical ventilation, ICU, and hospital stays.[8] However, paralytic use in ARDS cases remains controversial. When appropriately used, paralytics may aid successful mechanical ventilation; however, evidence has also suggested that mechanical ventilation in severe sepsis does not improve oxygen consumption and delivery.[8]

Source control

[edit]

Source control refers to physical interventions to control a focus of infection and reduce conditions favorable to microorganism growth or host defense impairment, such as drainage of pus from an abscess. It is one of the oldest procedures for the control of infections, giving rise to the Latin phrase Ubi pus, ibi evacua, and remains important despite the emergence of more modern treatments.[88][89]

Early goal-directed therapy

[edit]

Early goal directed therapy (EGDT) is an approach to the management of severe sepsis during the initial 6 hours after diagnosis.[90] It is a step-wise approach, with the physiologic goal of optimizing cardiac preload, afterload, and contractility.[91] It includes giving early antibiotics.[91] EGDT also involves monitoring of hemodynamic parameters and specific interventions to achieve key resuscitation targets which include maintaining a central venous pressure between 8–12 mmHg, a mean arterial pressure of between 65 and 90 mmHg, a central venous oxygen saturation (ScvO2) greater than 70% and a urine output of greater than 0.5 mL/kg/hour. The goal is to optimize oxygen delivery to tissues and achieve a balance between systemic oxygen delivery and demand.[91] An appropriate decrease in serum lactate may be equivalent to ScvO2 and easier to obtain.[92]

In the original trial, early goal-directed therapy was found to reduce mortality from 46.5% to 30.5% in those with sepsis,[91] and the Surviving Sepsis Campaign has been recommending its use.[8] However, three more recent large randomized control trials (ProCESS, ARISE, and ProMISe), did not demonstrate a 90-day mortality benefit of early goal-directed therapy when compared to standard therapy in severe sepsis.[93] It is likely that some parts of EGDT are more important than others.[93] Following these trials, the use of EGDT is still considered reasonable.[94]

Newborns

[edit]

Neonatal sepsis can be difficult to diagnose as newborns may be asymptomatic.[95] If a newborn shows signs and symptoms suggestive of sepsis, antibiotics are immediately started and are either changed to target a specific organism identified by diagnostic testing or discontinued after an infectious cause for the symptoms has been ruled out.[96] Despite early intervention, death occurs in 13% of children who develop septic shock, with the risk partly based on other health problems. For those without multiple organ system failures or who require only one inotropic agent, mortality is low.[97]

Other

[edit]

Treating fever in sepsis, including people in septic shock, has not been associated with any improvement in mortality over a period of 28 days.[98] Treatment of fever still occurs for other reasons.[99][100]

A 2012 Cochrane review concluded that N-acetylcysteine does not reduce mortality in those with SIRS or sepsis and may even be harmful.[101]

Recombinant activated protein C (drotrecogin alpha) was originally introduced for severe sepsis (as identified by a high APACHE II score), where it was thought to confer a survival benefit.[90] However, subsequent studies showed that it increased adverse events—bleeding risk in particular—and did not decrease mortality.[102] It was removed from sale in 2011.[102] Another medication known as eritoran also has not shown benefit.[103]

In those with high blood sugar levels, insulin to bring it down to 7.8–10 mmol/L (140–180 mg/dL) is recommended, with lower levels potentially worsening outcomes.[104] Glucose levels taken from capillary blood should be interpreted with care because such measurements may not be accurate. If a person has an arterial catheter, arterial blood is recommended for blood glucose testing.[5]

Intermittent or continuous renal replacement therapy may be used if indicated. However, sodium bicarbonate is not recommended for a person with lactic acidosis secondary to hypoperfusion. Low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), and mechanical prophylaxis with intermittent pneumatic compression devices are recommended for any person with sepsis at moderate to high risk of venous thromboembolism.[5] Stress ulcer prevention with proton-pump inhibitor (PPI) and H2 antagonist are useful in a person with risk factors of developing upper gastrointestinal bleeding (UGIB) such as on mechanical ventilation for more than 48 hours, coagulation disorders, liver disease, and renal replacement therapy.[5] Achieving partial or full enteral feeding (delivery of nutrients through a feeding tube) is chosen as the best approach to provide nutrition for a person who is contraindicated for oral intake or unable to tolerate orally in the first seven days of sepsis when compared to intravenous nutrition. However, omega-3 fatty acids are not recommended as immune supplements for a person with sepsis or septic shock. The usage of prokinetic agents such as metoclopramide, domperidone, and erythromycin is recommended for those who are septic and unable to tolerate enteral feeding. However, these agents may precipitate prolongation of the QT interval and consequently provoke a ventricular arrhythmia such as torsades de pointes. The usage of prokinetic agents should be reassessed daily and stopped if no longer indicated.[5]

People in sepsis may have micronutrient deficiencies, including low levels of vitamin C.[105] Reviews mention that an intake of 3.0 g/day, which requires intravenous administration, may be needed to maintain normal plasma concentrations in people with sepsis or severe burn injury.[106][107]

Prognosis

[edit]

Sepsis proves fatal for approximately 24.4% of people, and septic shock proves fatal for 34.7% of people within 30 days (with fatality rates for sepsis and septic shock being 32.2% and 38.5% after 90 days, respectively).[108] Lactate is a useful method of determining prognosis, with those who have a level greater than 4 mmol/L having a mortality of 40% and those with a level of less than 2 mmol/L having a mortality of less than 15%.[51]

There are several prognostic stratification systems, such as APACHE II and Mortality in Emergency Department Sepsis. APACHE II factors in the person's age, underlying condition, and various physiologic variables to yield estimates of the risk of dying of severe sepsis. Of the individual covariates, the severity of the underlying disease most strongly influences the risk of death. Septic shock is also a strong predictor of short- and long-term mortality. Case-fatality rates are similar for culture-positive and culture-negative severe sepsis. The Mortality in Emergency Department Sepsis (MEDS) score is simpler and useful in the emergency department environment.[109]

Some people may experience severe long-term cognitive decline following an episode of severe sepsis, but the absence of baseline neuropsychological data in most people with sepsis makes the incidence of this difficult to quantify or study.[110] Other complications in those who survive sepsis include functional decline, being unable to return to work, or in pediatrics being unable to regain baseline health status.[9] Immune dysfunction and hyperinflammation may persist long after sepsis has resolved.[9]

The global mortality rate from sepsis declined from 50% in 1990 to 35% in 2017. However, the incidence and mortality of sepsis is difficult to quantify due to changing definitions of sepsis and increased recognition of the complication over time.[9][111]

Epidemiology

[edit]

Sepsis causes millions of deaths globally each year and is the most common cause of death in people who have been hospitalized.[3][90] The number of new cases of sepsis worldwide is estimated to be 18 million cases per year.[112] In the United States, sepsis affects approximately 3 in 1,000 people,[51] and severe sepsis contributes to more than 200,000 deaths per year.[113]

Sepsis occurs in 1–2% of all hospitalizations and accounts for as much as 25% of ICU bed utilization. As it is rarely reported as a primary diagnosis (often being a complication of cancer or other illness), the incidence, mortality, and morbidity rates of sepsis are probably underestimated.[31] A study of U.S. states found approximately 651 hospital stays per 100,000 population with a sepsis diagnosis in 2010.[114] It is the second-leading cause of death in non-coronary intensive care unit (ICU) and the tenth-most-common cause of death overall (the first being heart disease).[115] Children under 12 months of age and elderly people have the highest incidence of severe sepsis.[31] Among people from the U.S. who had multiple sepsis hospital admissions in 2010, those who were discharged to a skilled nursing facility or long-term care following the initial hospitalization were more likely to be readmitted than those discharged to another form of care.[114] A study of 18 U.S. states found that amongst people with Medicare in 2011, sepsis was the second most common principal reason for readmission within 30 days.[116]

Several medical conditions increase a person's susceptibility to infection and the development of sepsis. Common sepsis risk factors include age (especially the very young and old); conditions that weaken the immune system such as cancer, diabetes, or the absence of a spleen; and major trauma and burns.[1][117][118]

From 1979 to 2000, data from the United States National Hospital Discharge Survey showed that the incidence of sepsis increased fourfold, to 240 cases per 100,000 population, with a higher incidence in men when compared to women. However, the global prevalence of sepsis has been estimated to be higher in women.[17] During the same time frame, the in-hospital case fatality rate was reduced from 28% to 18%. However, according to the nationwide inpatient sample from the United States, the incidence of severe sepsis increased from 200 per 10,000 population in 2003 to 300 cases in 2007 for a population aged more than 18 years. The incidence rate is particularly high among infants, with an incidence of 500 cases per 100,000 population. Mortality related to sepsis increases with age, from less than 10% in the age group of 3 to 5 years to 60% by the sixth decade of life.[26] The increase in the average age of the population, alongside the presence of more people with chronic diseases or on immunosuppressive medications, and also the increase in the number of invasive procedures being performed, has led to an increased rate of sepsis.[27]

History

[edit]
Personification of septicemia, carrying a spray can marked "Poison"

The term "σήψις" (sepsis) was introduced by Hippocrates in the fourth century BC, and it meant the process of decay or decomposition of organic matter.[119][120][121] In the eleventh century, Avicenna used the term "blood rot" for diseases linked to severe purulent process. Though severe systemic toxicity had already been observed, it was only in the 19th century that the specific term – sepsis – was used for this condition.

The terms "septicemia", also spelled "septicaemia", and "blood poisoning" referred to the microorganisms or their toxins in the blood. The International Statistical Classification of Diseases and Related Health Problems (ICD) version 9, which was in use in the US until 2013, used the term septicemia with numerous modifiers for different diagnoses, such as "Streptococcal septicemia".[122] All those diagnoses have been converted to sepsis, again with modifiers, in ICD-10, such as "Sepsis due to streptococcus".[122]

The current terms are dependent on the microorganism that is present: bacteremia if bacteria are present in the blood at abnormal levels and are the causative issue, viremia for viruses, and fungemia for a fungus.[123]

By the end of the 19th century, it was widely believed that microbes produced substances that could injure the mammalian host and that soluble toxins released during infection caused the fever and shock that were commonplace during severe infections. Pfeiffer coined the term endotoxin at the beginning of the 20th century to denote the pyrogenic principle associated with Vibrio cholerae. It was soon realized that endotoxins were expressed by most and perhaps all gram-negative bacteria. The lipopolysaccharide character of enteric endotoxins was elucidated in 1944 by Shear.[124] The molecular character of this material was determined by Luderitz et al. in 1973.[125]

It was discovered in 1965 that a strain of C3H/HeJ mouse was immune to the endotoxin-induced shock.[126] The genetic locus for this effect was dubbed Lps. These mice were also found to be hyper-susceptible to infection by gram-negative bacteria.[127] These observations were finally linked in 1998 by the discovery of the toll-like receptor gene 4 (TLR 4).[128] Genetic mapping work, performed over five years, showed that TLR4 was the sole candidate locus within the Lps critical region; this strongly implied that a mutation within TLR4 must account for the lipopolysaccharide resistance phenotype. The defect in the TLR4 gene that led to the endotoxin-resistant phenotype was discovered to be due to a mutation in the cytoplasm.[129]

Controversy occurred in the scientific community over the use of mouse models in research into sepsis in 2013 when scientists published a review of the mouse immune system compared to the human immune system and showed that on a systems level, the two worked very differently; the authors noted that as of the date of their article over 150 clinical trials of sepsis had been conducted in humans, almost all of them supported by promising data in mice and that all of them had failed. The authors called for abandoning the use of mouse models in sepsis research; others rejected that but called for more caution in interpreting the results of mouse studies,[130] and more careful design of preclinical studies.[131][132][133][134] One approach is to rely more on studying biopsies and clinical data from people who have had sepsis, to try to identify biomarkers and drug targets for intervention.[135]

Society and culture

[edit]

Economics

[edit]

Sepsis was the most expensive condition treated in United States' hospital stays in 2013, at an aggregate cost of $23.6 billion for nearly 1.3 million hospitalizations.[136] Costs for sepsis hospital stays more than quadrupled since 1997 with an 11.5 percent annual increase.[137] By payer, it was the most costly condition billed to Medicare and the uninsured, the second-most costly billed to Medicaid, and the fourth-most costly billed to private insurance.[136]

Education

[edit]

A large international collaboration entitled the "Surviving Sepsis Campaign" was established in 2002[138] to educate people about sepsis and to improve outcomes with sepsis. The Campaign has published an evidence-based review of management strategies for severe sepsis, with the aim of publishing a complete set of guidelines in subsequent years.[90] The guidelines were updated in 2016[139] and again in 2021.[140]

Awareness

[edit]

Sepsis Alliance is a charitable organization based in the United States that was created to raise sepsis awareness among both the general public and healthcare professionals.[141] In 2011, September was declared Sepsis Awareness Month. One year later, the Global Sepsis Alliance declared September 13 World Sepsis Day.[142]

Research

[edit]
Phenotypic strategy switches of microbes capable of provoking sepsis

Some authors suggest that initiating sepsis by the normally mutualistic (or neutral) members of the microbiome may not always be an accidental side effect of the deteriorating host immune system. Rather, it is often an adaptive microbial response to a sudden decline of host survival chances. Under this scenario, the microbe species provoking sepsis benefit from monopolizing the future cadaver, utilizing its biomass as decomposers, and then transmitting through soil or water to establish mutualistic relations with new individuals. The bacteria Streptococcus pneumoniae, Escherichia coli, Proteus spp., Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella spp., Clostridium spp., Lactobacillus spp., Bacteroides spp. and the fungi Candida spp. are all capable of such a high level of phenotypic plasticity. Not all cases of sepsis arise through such adaptive microbial strategy switches.[143]

Paul E. Marik's "Marik protocol", also known as the "HAT" protocol, proposed a combination of hydrocortisone, vitamin C, and thiamine as a treatment for preventing sepsis for people in intensive care. Marik's initial research, published in 2017, showed dramatic evidence of benefit, leading to the protocol becoming popular among intensive care physicians, especially after the protocol received attention on social media and National Public Radio, leading to criticism of science by press conference from the wider medical community. Subsequent independent research failed to replicate Marik's positive results, indicating the possibility that they had been compromised by bias.[144] A systematic review of trials in 2021 found that the claimed benefits of the protocol could not be confirmed.[145]

Overall, the evidence for any role of vitamin C in the treatment of sepsis remains unclear as of 2021.[146]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Sepsis is a life-threatening characterized by the body's extreme and dysregulated to an , which triggers widespread and can lead to tissue damage, , and . It arises when an existing —often bacterial, but also viral, fungal, or parasitic—escalates uncontrollably, affecting multiple organ systems and potentially progressing to if untreated. Globally, sepsis imposes a significant burden, with an estimated 166 million cases and 21 million deaths in 2021. Recent estimates indicate a substantial increase in reported incidence compared to earlier studies, highlighting the growing global challenge. , there were approximately 2.5 million sepsis-related hospitalizations in 2021, resulting in about 302,000 in-hospital deaths, and it contributes to one in three hospital deaths. The condition disproportionately affects vulnerable populations, including neonates, children under five (with 20 million cases annually), older adults, pregnant women, and those with weakened immune systems, with the highest incidence in low- and lower-middle-income countries. Common causes of sepsis stem from infections in sites such as the lungs (e.g., ), urinary tract, gastrointestinal system, skin wounds, or bloodstream, often exacerbated by factors like . Risk factors include extremes of age (infants and those over 65), chronic conditions like , cancer, , kidney disease, or (COPD), recent hospitalization or stays, invasive medical devices (e.g., catheters), and recent use of antibiotics or corticosteroids. Symptoms typically emerge rapidly and include fever or , rapid , fast and , or disorientation, clammy or sweaty skin, extreme pain, and ; in children, signs may involve fast breathing, lethargy, or poor feeding. If sepsis advances to , additional severe indicators appear, such as critically low , inability to stand, profound sleepiness, and reduced urine output, signaling imminent organ failure. Diagnosis relies on clinical assessment combined with laboratory tests, including blood analyses for markers, clotting abnormalities, organ function, oxygen levels, and electrolytes, as well as imaging (e.g., X-rays, CT scans) and cultures from , wounds, or respiratory samples to pinpoint the infection source. Treatment must be prompt and aggressive, typically involving broad-spectrum intravenous antibiotics adjusted based on identified pathogens, fluid resuscitation to stabilize , vasopressors for persistent , and supportive measures like , , or dialysis in an . may be necessary to drain abscesses or remove infected tissue. Early intervention within the first hour of recognition dramatically improves outcomes, as delays can increase mortality rates to 30-40% in cases. Prevention focuses on reducing infection risks through practices like hand hygiene, vaccinations (e.g., against or ), timely treatment of wounds or illnesses, and infection control in healthcare settings. Despite advances, sepsis remains a major contributor to maternal, neonatal, and , underscoring the need for global strategies aligned with for health.

Clinical Presentation

Signs and Symptoms

Sepsis manifests through a range of observable signs and subjective symptoms that reflect the body's dysregulated response to . Common signs include fever (temperature greater than 38°C) or (temperature less than 36°C), (heart rate exceeding 90 beats per minute), (respiratory rate greater than 20 breaths per minute), altered mental status such as or disorientation, and, in severe cases, (systolic less than 90 mm Hg). Symptoms often reported by patients encompass , profound , , localized at the site of , and (reduced urine output less than 0.5 mL/kg/hour). These manifestations can vary in intensity and may not all be present simultaneously, emphasizing the need for clinical vigilance. Historically, the (SIRS) criteria provided a framework for identifying potential sepsis, requiring at least two of the following: abnormal temperature, , or , and abnormal count. Introduced in 1991 by the American College of Chest Physicians and Society of Critical Care Medicine, SIRS was used to define sepsis as the syndrome plus a suspected . However, its limitations include high sensitivity but low specificity, as it frequently occurs in noninfectious conditions like trauma or and fails to predict or distinguish infectious from noninfectious causes. Studies have shown that up to one in eight patients with and organ failure do not meet SIRS criteria, leading to its replacement in the 2016 Sepsis-3 definitions. The presentation of sepsis can differ based on the primary site of infection, influencing both local and systemic features. For respiratory infections such as , patients often exhibit worsening cough, , pleuritic , and . In gastrointestinal sources, symptoms may include , distention, rigidity, decreased bowel sounds, , or emesis. Genitourinary infections commonly present with , urinary frequency, , lower , or costovertebral tenderness, while skin or soft tissue infections show ecchymosis, petechiae, bullous lesions, , or purulent drainage. These site-specific signs accompany the general systemic symptoms, aiding in source identification. In pediatric patients, sepsis signs and symptoms can be subtler and more variable than in adults, often mimicking other common childhood illnesses. Infants and young children may display poor feeding, , , mottled skin, prolonged , or difficulty waking, alongside fever or and . Older children might report extreme pain, clammy skin, or rapid breathing, but altered mental status can manifest as or reduced responsiveness. These presentations underscore the importance of recognizing nonspecific indicators in this vulnerable group. Elderly individuals frequently exhibit atypical or muted symptoms due to age-related immune changes and comorbidities, with fever absent in up to 30% of cases and associated with higher mortality. Common features include generalized weakness, agitation, , anorexia, , falls, or , rather than classic signs like chills or , which may be blunted. Altered mental status often predominates, complicating timely recognition in this population.

Progression and Stages

Sepsis typically originates from an uncomplicated , in which the is contained at a local site without eliciting a systemic inflammatory response. If the overwhelms local defenses or the host response becomes dysregulated, it progresses to sepsis, defined under the Sepsis-3 framework as life-threatening caused by a dysregulated host response to , clinically identified by an acute increase in the Sequential Organ Failure Assessment () score of 2 or more points. This stage represents a critical transition marked by worsening organ function, often with elevated lactate levels exceeding 2 mmol/L indicating tissue hypoperfusion. Many educational and public health resources describe sepsis progression in three stages: 1. Sepsis (initial stage), where infection triggers systemic inflammation, often meeting Systemic Inflammatory Response Syndrome (SIRS) criteria such as abnormal temperature, heart rate, respiratory rate, or white blood cell count; 2. Severe sepsis, where organ dysfunction begins, manifested by reduced urine output, altered mental status, or low platelets; 3. Septic shock, characterized by a severe drop in blood pressure unresponsive to fluid resuscitation, leading to multi-organ failure. Note that the term "severe sepsis" is largely deprecated in current medical practice, as organ dysfunction is now inherent to the sepsis definition under Sepsis-3. In earlier consensus definitions, such as those from the 2001 International Sepsis Definitions Conference, the progression was categorized into distinct stages: sepsis (systemic inflammatory response to ), severe sepsis (sepsis with , , or hypoperfusion abnormalities), and (severe sepsis with persistent despite fluid ). Severe sepsis highlights the escalation where or signs of hypoperfusion, such as or altered mental status, emerge as key markers, signaling the need for urgent intervention to prevent further deterioration. The Sepsis-3 framework integrates severe sepsis into the broader sepsis category, emphasizing the continuum of severity driven by the dysregulated response rather than rigid staging. Advancement to septic shock occurs when circulatory failure persists, requiring vasopressors to maintain a of at least 65 mm Hg, alongside serum lactate greater than 2 mmol/L after adequate volume resuscitation. This stage carries a mortality exceeding 40% and underscores the profound metabolic and cellular derangements. The overall time course of progression can be alarmingly rapid, often unfolding within hours from initial infection to , particularly in vulnerable populations such as the elderly, infants, or those with . Early recognition of these transition markers is essential, as delays in treatment can accelerate the continuum toward irreversible organ damage.

Pathogenesis

Causes of Infection

Sepsis arises from infections caused by a variety of microbial pathogens that invade the body and trigger a dysregulated immune response. The most common causative agents are bacteria, which account for the majority of cases, followed by fungi, viruses, and rarely parasites. Among bacteria, gram-negative species such as Escherichia coli and Klebsiella pneumoniae predominate, often comprising over 30% and 10% of isolates respectively, while gram-positive bacteria like Staphylococcus aureus are also frequent. Fungal pathogens, particularly Candida species such as Candida albicans, cause approximately 5-15% of sepsis cases, especially in critically ill patients. Viral infections, including influenza and SARS-CoV-2, can lead to sepsis, though less commonly than bacterial causes. Parasitic infections, such as those from Plasmodium species in severe malaria or Strongyloides stercoralis, are rare contributors to sepsis globally. The primary sites of infection leading to sepsis include the lungs, , urinary tract, and soft tissues, and bloodstream. Pneumonia represents the most frequent source, accounting for 25-50% of cases depending on the population studied. Abdominal infections, such as from bowel perforation, contribute around 10-20% of sepsis episodes. Urinary tract infections, often involving ascending bacterial spread, are responsible for up to 30% of severe sepsis instances. and soft tissue infections, including or , rank as the third most common origin. Bloodstream infections, typically from direct microbial entry, make up about 15% of cases. Sepsis can be classified as community-acquired or hospital-acquired (nosocomial), with the latter often carrying higher mortality due to resistant pathogens. Community-acquired sepsis commonly stems from respiratory or urinary sources in outpatient settings, while hospital-acquired cases frequently involve or intra-abdominal infections post-surgery. Nosocomial sepsis accounts for a significant proportion of infections, exceeding 40% mortality in some cohorts. Medical devices and procedures elevate the risk of infection-related sepsis through breaches in sterile barriers. Intravenous lines and central catheters are common culprits in catheter-related bloodstream infections, contributing to up to 50% higher mortality in affected patients. Surgical interventions can introduce pathogens via contaminated instruments or wounds, leading to surgical site infections that progress to sepsis.

Pathophysiological Mechanisms

Sepsis is defined as life-threatening caused by a dysregulated host response to , as established by the Sepsis-3 consensus criteria, which emphasize the central role of immune dysregulation in driving pathological outcomes. This dysregulation manifests as an imbalance between proinflammatory and responses, leading to both excessive and subsequent , which collectively contribute to multi-organ failure. The pathophysiological cascade begins with infection triggering the activation of innate immunity through pathogen-associated molecular patterns (PAMPs) recognized by toll-like receptors (TLRs) on immune cells, initiating a systemic inflammatory response. This response escalates into a , characterized by massive release of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which amplify inflammation, recruit neutrophils, and cause collateral tissue damage. Endothelial cells are particularly vulnerable, suffering damage from cytokines and damage-associated molecular patterns (DAMPs) released by injured tissues, resulting in increased , loss of properties, and exposure of subendothelial procoagulant surfaces. This promotes microvascular , impairing tissue perfusion and exacerbating organ hypoperfusion, a key driver of dysfunction. Coagulation abnormalities further compound these effects, with sepsis frequently inducing (DIC) through an imbalance of procoagulant factors like and reduced anticoagulant mechanisms, such as and . In DIC, widespread microvascular thrombi consume clotting factors and platelets, leading to both thrombotic and hemorrhagic complications, while suppressed perpetuates the . Metabolic derangements arise from this hypoperfusion, including due to anaerobic in hypoxic tissues, where elevated lactate levels (>2 mmol/L) serve as a marker of severity and predictor of mortality. Overall, these interconnected mechanisms—, endothelial injury, , and metabolic stress—culminate in the life-threatening central to sepsis.

Microbial Factors

Microbial factors play a crucial role in determining the severity of sepsis by enabling to invade tissues, evade host defenses, and trigger dysregulated inflammatory responses. These factors include structural components, secreted toxins, and adaptive mechanisms that enhance pathogen survival and dissemination during . Among , both Gram-negative and Gram-positive contribute significantly, with their elements directly influencing the progression from localized to systemic sepsis. Virulence factors such as endotoxins and exotoxins are central to bacterial . In , endotoxins—primarily (LPS) components of the outer membrane—trigger intense proinflammatory release upon release during bacterial lysis or growth, leading to endothelial damage, vascular leakage, and hemodynamic instability characteristic of . For instance, LPS from and binds on immune cells, amplifying the systemic inflammatory response. In contrast, like and produce exotoxins, including superantigens such as (TSST-1) and streptococcal pyrogenic exotoxins, which non-specifically activate T cells by bridging and T-cell receptors, causing massive storms and toxic shock-like sepsis. These superantigens can stimulate up to 20-30% of T lymphocytes, far exceeding conventional responses, thereby exacerbating sepsis severity. Biofilm formation represents another key microbial strategy that heightens sepsis risk, particularly in device-related infections. Pathogens such as Staphylococcus epidermidis and Pseudomonas aeruginosa form adherent biofilms on indwelling medical devices like catheters and prosthetics, creating a protective extracellular matrix of polysaccharides, proteins, and DNA that shields bacteria from immune clearance and antibiotics. This matrix impedes phagocytosis by neutrophils and macrophages while allowing persistent low-level bacteremia, which can seed distant sites and precipitate sepsis. In S. aureus biofilms, quorum-sensing systems further regulate virulence gene expression, promoting immune evasion through reduced opsonization and complement activation. Antibiotic resistance patterns among pathogens substantially increase the likelihood and severity of sepsis by delaying effective treatment and allowing unchecked microbial proliferation. Methicillin-resistant Staphylococcus aureus (MRSA) exemplifies this, with its acquisition of the mecA gene conferring resistance to beta-lactam antibiotics, leading to higher rates of invasive infections and sepsis in hospital settings. Similarly, multidrug-resistant , such as carbapenem-resistant and extended-spectrum beta-lactamase-producing , exhibit resistance to multiple drug classes via mechanisms like efflux pumps and enzymatic degradation, resulting in prolonged bacteremia and elevated mortality in septic patients. These resistant strains are associated with up to 50% higher sepsis-related mortality compared to susceptible counterparts, underscoring their role in worsening outcomes. Fungal and viral pathogens contribute to sepsis through distinct virulence traits that exploit infection niches. In fungal sepsis, Aspergillus fumigatus—a common opportunistic mold—employs conidial hydrophobins for airborne dispersal and tissue adhesion, while hyphal growth releases gliotoxin and other mycotoxins that suppress immune effector functions and induce , facilitating angioinvasion and disseminated . This mold's thermotolerance and ability to thrive at 37°C enable rapid proliferation in lung tissues, often leading to invasive and secondary sepsis in at-risk scenarios. For viral sepsis, pathogens like influenza virus or exhibit via rapid replication and immune modulation; for example, influenza's neuraminidase facilitates viral spread and endothelial disruption, while its promotes dysregulation, culminating in viral-induced sepsis with bacterial . Opportunistic viruses in polymicrobial sepsis further amplify severity by impairing pathogen clearance, though remain the predominant trigger.

Host Factors

Host factors play a critical role in determining an individual's susceptibility to sepsis and the severity of the disease, encompassing inherent biological vulnerabilities that modulate immune responses to . These factors include age-related immunocompromise, where neonates and the elderly exhibit heightened due to or senescent immune systems, respectively; for instance, the incidence of sepsis is notably higher in infants and older adults compared to other age groups. Recent research in a polymicrobial sepsis model in mice demonstrates age-dependent tradeoffs in disease tolerance, a defense strategy that limits physiological damage without directly eliminating the pathogen. In young hosts, the cardiac Foxo1–Trim63 axis mediates protective effects against sepsis-induced cardiac remodeling, multi-organ injury, and mortality. Conversely, in aged hosts, this axis drives pathogenesis and death, illustrating antagonistic pleiotropy with implications for tailoring therapies to the patient's age. Chronic diseases such as and cancer further exacerbate this susceptibility by impairing immune function and promoting persistent inflammation, leading to poorer outcomes in septic patients. Similarly, acquired from conditions like or treatments such as diminishes the body's ability to mount an effective response to pathogens, increasing the likelihood of severe sepsis. Genetic polymorphisms represent another key host factor influencing sepsis, particularly variants in genes involved in innate immunity. For example, polymorphisms in the (TLR4) gene, such as Asp299Gly, have been associated with altered responses to bacterial lipopolysaccharides, potentially conferring either increased risk or protective effects against sepsis depending on the specific variant and population studied. These genetic variations can affect the recognition of microbial components, thereby modulating the inflammatory cascade and contributing to heterogeneous disease severity among individuals exposed to similar infections. Beyond immunocompromise and genetics, comorbidities like , , and significantly impact sepsis progression by altering , immune regulation, and organ recovery. is linked to a dysregulated during sepsis, characterized by elevated proinflammatory cytokines and , which can worsen outcomes despite potential survival advantages in some cohorts due to metabolic reserves. Liver and kidney diseases impair and , respectively, complicating sepsis and increasing mortality risk through heightened vulnerability to end-organ dysfunction. Socioeconomic factors indirectly modify sepsis severity as host-related modifiers, primarily through delayed access to care, which allows infections to progress unchecked in underserved populations. Individuals with lower often face barriers to timely medical intervention, resulting in more advanced disease at presentation and elevated mortality rates.

Diagnosis

Definitions and Criteria

Sepsis has evolved through several definitional frameworks, with early criteria emphasizing but later shifting toward and host response dysregulation. The (SIRS) criteria, introduced in 1992, defined sepsis as plus two or more of the following: >38°C or <36°C, heart rate >90 beats/min, respiratory rate >20 breaths/min or PaCO₂ <32 mmHg, and white blood cell count >12,000/mm³, <4,000/mm³, or >10% bands. However, these criteria demonstrated low specificity, capturing non-infectious conditions and failing to predict poor outcomes reliably, leading to their replacement in subsequent consensus definitions. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), published in 2016, redefined sepsis as life-threatening caused by a dysregulated host response to . is operationally identified by an acute increase of ≥2 points in the Sequential Organ Failure Assessment (, a validated tool developed in 1996 to quantify dysfunction across six organ systems: respiratory (PaO₂/FiO₂ ratio), cardiovascular ( or vasopressor use), hepatic (), coagulation (platelets), renal ( or urine output), and neurological (). Each system is scored from 0 (normal) to 4 (most abnormal), yielding a total score ranging from 0 to 24, with higher values correlating to increased mortality risk. For rapid bedside screening outside intensive care units, the quick SOFA (qSOFA) score was introduced, assigning 1 point each for respiratory rate ≥22 breaths/min, altered mentation ( <15), and systolic blood pressure ≤100 mmHg; a score ≥2 indicates high risk for poor outcomes in suspected and prompts further evaluation. Septic shock, under Sepsis-3, is identified as a subset of sepsis with profound circulatory and cellular/metabolic abnormalities, specifically requiring vasopressors to maintain mean arterial pressure ≥65 mmHg and serum lactate >2 mmol/L despite adequate volume resuscitation, associated with hospital mortality exceeding 40%. The 2025 update to the S3 guidelines on sepsis prevention, , , and follow-up care affirms the Sepsis-3 definitions while emphasizing early recognition through integrated screening tools like qSOFA to improve timely intervention.

Clinical Assessment

Clinical assessment of sepsis begins with a focused to identify potential sources of and risk factors that heighten suspicion for the condition. Clinicians should inquire about recent or ongoing infections, such as symptoms like or dyspnea, urinary symptoms like , or skin changes indicating or . Travel history, animal or environmental exposures, and recent procedures or hospitalizations are critical, as they may point to unusual pathogens or device-related infections. Comorbidities, including diabetes, chronic lung disease, immunosuppression from medications or conditions like HIV, and indwelling devices such as catheters, should be elicited, as these increase vulnerability to sepsis. The serves as a for suspecting sepsis, emphasizing and targeted evaluation for sources. screening includes assessment of temperature (fever or ), heart rate ( >90 bpm), respiratory rate ( >20 breaths/min), blood pressure ( <90/60 mmHg), and oxygen saturation to detect systemic derangements. To identify the source, clinicians perform directed examinations: lung auscultation for crackles, wheezes, or consolidation suggestive of pneumonia; abdominal palpation for tenderness, guarding, or distention indicating intra-abdominal ; and inspection of skin, wounds, or catheter sites for erythema, warmth, or discharge. Additional signs of hypoperfusion, such as altered mental status, cool extremities, or prolonged capillary refill, further support suspicion. Screening tools facilitate early detection of sepsis in hospital settings by alerting providers to physiological deterioration. The National Early Warning Score (NEWS), developed by the Royal College of Physicians, aggregates scores from vital signs including respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness, and temperature to quantify illness severity and trigger responses. A NEWS score of 5 or higher prompts evaluation for sepsis, outperforming other tools like qSOFA in sensitivity for identifying at-risk patients in emergency departments and wards. Electronic alerts based on such scores enable proactive intervention, particularly in non-intensive care units. Rapid assessment protocols, such as the Surviving Sepsis Campaign's Hour-1 Bundle, guide bedside evaluation to expedite suspicion and initial steps. For patients with suspected sepsis, the bundle recommends immediate measurement of lactate to assess severity, obtaining blood cultures prior to antibiotics to identify pathogens, and administering broad-spectrum antimicrobials within one hour if infection likelihood is high. These elements integrate with history and examination to prioritize urgent care, emphasizing continuous re-evaluation for source control and alternative diagnoses. Performance improvement programs incorporating these protocols, alongside screening tools like NEWS, are strongly endorsed to enhance recognition. Challenges in clinical assessment arise particularly in atypical presentations, such as in elderly patients who may lack classic signs. Older adults often present afebrile, with fever absent in 30-50% of cases due to blunted immune responses and reduced cytokine production, instead manifesting subtle symptoms like confusion, lethargy, falls, or incontinence. This nonspecific profile, compounded by comorbidities and frailty, delays suspicion and necessitates a high index of vigilance, detailed history from caregivers, and comprehensive examination to avoid under-recognition.

Biomarkers and Laboratory Tests

Blood cultures remain the gold standard for identifying the causative pathogen in sepsis, with guidelines recommending collection from at least two peripheral sites prior to initiating antimicrobial therapy to avoid delays exceeding 45 minutes. Positive cultures confirm infection and guide targeted therapy, though results may take 24-72 hours, and false negatives can occur due to prior antibiotic exposure or inadequate sampling. A complete blood count often reveals abnormalities in sepsis, including leukocytosis (white blood cell count >12,000/mm³) or (<4,000/mm³), reflecting the systemic inflammatory response, and thrombocytopenia (platelet count <150,000/mm³), which correlates with disease severity and increased mortality risk. These findings contribute to scoring systems like SIRS and SOFA but lack high specificity, as they can occur in non-infectious conditions. Lactate measurement is recommended in all patients suspected of sepsis to assess tissue hypoperfusion, with levels >2 mmol/L indicating severity and guiding efforts to normalize values. Elevated lactate predicts poor outcomes and supports early intervention, though it is not specific to and can rise in other states of shock. (PCT) serves as a for bacterial likelihood, with levels >0.5 ng/mL suggesting sepsis over non-infectious , aiding in by supporting discontinuation after 3-5 days if levels decline. However, guidelines advise against using PCT alone to initiate antimicrobials due to variable sensitivity (around 82%) and potential elevations in viral or non-infectious scenarios. (CRP), an acute-phase reactant, rises within 6-12 hours of (levels >100 mg/L in severe cases) and helps monitor response to but is less specific than PCT, with sensitivity around 75% and frequent false positives in chronic . Renal function tests, particularly serum creatinine (>1.2 mg/dL), evaluate in sepsis, while hepatic tests like total (>1.2 mg/dL) detect liver dysfunction; both are integral to SOFA scoring for . studies, including prolonged (PT)/international normalized ratio (INR >1.5) and reduced fibrinogen (<150 mg/dL), signal disseminated intravascular coagulation, a common complication increasing mortality. Emerging biomarkers include presepsin, a soluble CD14 subtype with high diagnostic accuracy (AUC 0.858, sensitivity 89%, specificity 89%) for early sepsis detection and severity correlation via SOFA scores. Soluble urokinase plasminogen activator receptor (suPAR) acts primarily as a prognostic marker, with elevated levels (>10 ng/mL) predicting mortality (AUROC 0.68-0.92) and linking immune dysregulation to outcomes, though it has limited diagnostic value (AUROC ~0.50) and is influenced by renal impairment. These markers show promise but face limitations such as false positives in non-infectious and the need for further validation in diverse populations.

End-Organ Dysfunction

End-organ dysfunction represents a critical consequence of sepsis, where the dysregulated inflammatory response to leads to impaired organ function, often progressing rapidly and contributing to high mortality rates. This multisystem involvement arises from mechanisms such as microvascular endothelial injury, tissue hypoperfusion, and cellular metabolic derangements, affecting vital organs and necessitating urgent clinical evaluation. In severe cases, dysfunction can involve multiple organs simultaneously, with the pattern and severity varying based on the underlying and host factors. Cardiovascular dysfunction in sepsis commonly manifests as hypotension and myocardial depression. results from systemic driven by inflammatory cytokines and production, leading to reduced vascular tone and relative , often requiring vasopressor support to maintain above 65 mm Hg. Myocardial depression occurs through downregulation of contractile proteins and mitochondrial dysfunction without cardiomyocyte , affecting approximately 33% of patients with reversible left ventricular systolic impairment and 50% with diastolic dysfunction, both linked to substantially elevated mortality risks of 60-80%. Respiratory dysfunction frequently presents as (ARDS) and , impairing and oxygenation. ARDS develops from endothelial glycocalyx degradation and alveolar capillary leakage induced by proinflammatory mediators, causing and ventilation-perfusion mismatch. This affects about 40% of sepsis patients, with quantified by a PaO₂/FiO₂ ratio below 300 mm Hg, and carries a of 35-46%. Renal dysfunction is characterized by (AKI), often progressing to the need for such as dialysis. AKI stems from renal microvascular , tubular epithelial cell due to hypoxia and , and reduced , occurring in over 50% of sepsis cases and associated with a 62% increase in in-hospital mortality. Clinical signs include and elevated serum levels exceeding 1.5 times baseline. Hepatic dysfunction typically involves and , reflecting impaired synthetic and detoxifying functions of the liver. arises from and hepatocellular injury secondary to sinusoidal endothelial damage and hypoxic , with levels rising above 2 mg/dL in affected patients. results from decreased production of clotting factors and , exacerbating bleeding risks and occurring in around 46% of cases, which correlates with higher 28-day mortality. Neurological dysfunction encompasses sepsis-associated encephalopathy and seizures, altering mental status and cognitive function. is driven by blood-brain barrier disruption, cerebral hypoperfusion, and neuroinflammatory responses, manifesting as or in up to 70% of patients and increasing the risk of seizures through imbalances. This form of dysfunction is particularly ominous, strongly associating with both short- and long-term mortality. The Sequential Organ Failure Assessment (SOFA) score provides a standardized method to quantify end-organ dysfunction across six systems—respiratory, , hepatic, cardiovascular, central nervous, and renal—each scored from 0 (normal) to 4 (most abnormal) based on clinical and laboratory parameters such as PaO₂/FiO₂ ratio, , platelet count, vasopressor use, , and . An acute change in total of 2 or more points consequent to signifies sepsis-induced dysfunction and predicts an in-hospital mortality risk exceeding 10%. Originally developed to describe organ in critically ill patients, the SOFA score facilitates consistent assessment of sepsis severity without guiding specific therapeutic decisions.

Differential Diagnosis

Sepsis presents with (SIRS) criteria, including fever, , , and , which can overlap with numerous non-infectious conditions that must be excluded through targeted evaluation. Common mimics include systemic inflammatory responses from non-infectious etiologies such as , severe burns, and , where the absence of a documented source, negative blood and tissue cultures, and specific diagnostic tests help differentiate them. For instance, elevated serum and levels confirm , while imaging like CT scans identifies trauma-related injuries without microbial involvement. Cardiogenic shock and also simulate sepsis through and but lack an infectious trigger. In , often due to acute , elevated levels, electrocardiographic changes, and reveal cardiac etiology, contrasting with sepsis's positive cultures or elevation. typically features rapid-onset urticaria, , and response to epinephrine, with levels peaking shortly after onset, unlike the persistent inflammatory markers in sepsis. Toxic shock syndrome (TSS), caused by toxin-producing or group A , closely resembles bacterial sepsis with fever, rash, and multi-organ failure but is distinguished by its characteristic diffuse erythroderma and 1-2 weeks later, often without widespread bacteremia. Confirmation involves isolation of the from a sterile site and fulfillment of CDC criteria, including mucous membrane hyperemia, which are absent in standard bacterial sepsis. In elderly patients, sepsis may manifest primarily as or altered mental status, mimicking non-infectious causes such as isolated urinary tract infections (UTIs) without systemic spread. Distinction relies on assessing for systemic signs like or elevated lactate, alongside biomarkers such as to confirm bacterial dissemination, as may be chronically elevated due to comorbidities. Negative cultures from non-sterile sites like alone, without evidence of end-organ dysfunction, support a of uncomplicated UTI over sepsis.

Diagnosis in Special Populations

Diagnosing sepsis in neonates presents unique challenges due to the nonspecific nature of symptoms, which often mimic other conditions common in this age group. Signs such as apnea, temperature instability (including or fever), poor feeding, , and are typical, rather than the classic focal symptoms seen in adults. These manifestations arise because the neonatal is immature, leading to subtle or vague presentations that delay recognition. Blood cultures, the gold standard for confirming bacterial sepsis, face limitations in neonates, with positivity rates as low as 3-8% due to low blood volumes sampled and prior maternal antibiotic exposure. To aid , biomarkers like (CRP), which rises within 6-8 hours and peaks at 24 hours, and (PCT), an early inflammatory marker, are commonly used; normal levels of these can help rule out with high negative predictive value. In elderly patients, sepsis often manifests with atypical presentations that deviate from standard criteria, complicating timely . Fever may be absent in up to 30-50% of cases due to blunted immune responses and age-related thermoregulatory changes, with baseline temperatures already 0.6-0.8°C lower than in younger adults. Instead, symptoms like confusion, altered mental status, generalized weakness, falls, or lethargy predominate, particularly in infections such as urinary tract infections or , where can be the sole indicator. The quick Sequential Organ Failure Assessment (qSOFA) score shows higher sensitivity in frail elderly populations, reaching up to 84.5% in those with frailty compared to non-frail patients, making it a useful bedside tool for risk stratification despite its general limitations.33938-8/fulltext) Immunocompromised individuals, including those with , solid organ transplants, or hematologic malignancies, require adjusted diagnostic approaches because of altered host responses and pathogen profiles. These patients are prone to s by opportunistic pathogens such as , species, or , which may not elicit typical signs of . Inflammatory markers like count, CRP, and PCT are often lower or blunted due to , reducing their reliability for early detection and necessitating reliance on clinical suspicion and . In severely immunocompromised hosts, the inflammatory response to can be minimal, sometimes presenting with fever as the only sign, underscoring the need for broad microbiological testing including cultures, PCR, and . During pregnancy and the postpartum period, sepsis diagnosis must account for physiological adaptations that overlap with normal changes, potentially masking or mimicking severity. Standard criteria like SIRS or qSOFA require modifications, as pregnancy involves elevated heart rates (up to 100 bpm), white blood cell counts (up to 25,000/mm³), and respiratory rates, which can inflate scores; tools like the Modified Obstetric Early Warning Score (MOEWS) or Sepsis in Obstetrics Score (SOS) are adapted for better specificity, with SOS ≥6 indicating high risk at 64% sensitivity. Amniotic fluid infections, such as chorioamnionitis, pose significant risks, often polymicrobial and linked to prolonged rupture of membranes or pyelonephritis, increasing sepsis odds by up to 33% and necessitating prompt evaluation via amniotic fluid analysis or placental cultures. Postpartum endometritis, arising from amniotic fluid contamination during delivery, further heightens vulnerability, particularly after cesarean sections. The 2025 update to the S3 guidelines on sepsis emphasizes tailored screening protocols for high-risk groups, including neonates, elderly, immunocompromised, and pregnant patients, to address diagnostic delays through population-specific thresholds and integrated use.

Management

Initial and Support

Upon suspicion of sepsis, initial aims to rapidly restore and oxygenation to prevent progression to and organ failure. The Surviving Sepsis Campaign (SSC) guidelines emphasize a structured "Hour-1 Bundle" to guide these interventions, promoting timely actions that have been associated with improved survival rates. This bundle integrates key elements to address hypoperfusion and control within the first hour of recognition. The Hour-1 Bundle includes measuring serum lactate levels to assess tissue perfusion; obtaining at least two blood cultures before antibiotic administration to identify the ; administering broad-spectrum intravenous antibiotics to cover likely etiologies; delivering a 30 mL/kg crystalloid fluid bolus to correct or elevated lactate; and initiating vasopressors, such as norepinephrine, if (MAP) remains below 65 mm Hg after fluids. Compliance with this bundle has been linked to reduced mortality, with studies showing a 10-20% absolute risk reduction when fully implemented early. The 2025 update to the S3 guidelines reinforces rapid adherence to this bundle, recommending lactate and antibiotics within 1 hour for and within 3 hours for sepsis without shock, while adapting SSC recommendations for individualized care. Respiratory support is integral to initial , starting with supplemental oxygen to maintain peripheral (SpO2) between 92% and 95% in non-hypoxemic patients, avoiding to prevent potential harm. In cases of (ARDS) complicating sepsis, which occurs in up to 40% of severe cases, early and with low tidal volumes (6 mL/kg predicted body weight) and plateau pressures below 30 cm H2O are recommended to minimize ventilator-induced lung injury. Prone positioning for more than 12 hours daily is advised for moderate-to-severe ARDS (PaO2/FiO2 ≤ 150 mm Hg) to improve oxygenation and outcomes. Hemodynamic monitoring facilitates goal-directed , typically involving arterial catheters for continuous tracking and central venous access for fluid and vasopressor administration if needed. Central venous oxygen saturation (ScvO2) monitoring, once central to early goal-directed therapy (EGDT), is now used selectively due to evidence from large trials showing no mortality benefit over standard care. The evolution of sepsis resuscitation reflects a shift from rigid EGDT protocols to more flexible, patient-centered approaches. The seminal 2001 Rivers trial demonstrated that EGDT—targeting 8-12 mm Hg, 65-90 mm Hg, urine output ≥0.5 mL/kg/h, and ScvO2 ≥70%—reduced 28-day mortality by 16% compared to usual care. However, subsequent multicenter trials (, ARISE, and ) involving over 4,000 patients found no survival advantage for EGDT over protocolized standard therapy, leading to de-emphasis on invasive targets like ScvO2. Current guidelines, including the 2021 SSC and 2025 S3 updates, advocate dynamic assessments like lactate clearance and time over strict goals, with permissive ( 60-65 mm Hg) considered in select patients without hypoperfusion to minimize fluid overload. This evolution prioritizes early bundle completion and individualized titration to balance and avoid complications like .

Antimicrobial Therapy

Antimicrobial therapy is a cornerstone of sepsis management, aimed at rapidly targeting the underlying to improve rates. Guidelines emphasize prompt initiation of intravenous antibiotics to cover the most likely pathogens, followed by optimization based on diagnostic results. This approach balances the need for broad initial coverage against the risks of and toxicity. The timing of antimicrobial administration is critical, with recommendations to start therapy within 1 hour of sepsis recognition, whether with or without shock, to minimize mortality risk. Delays in administration are associated with increased mortality; for instance, each hour of delay in the first 6 hours after the onset of in decreases by approximately 7.6%. This urgency is reflected in strong recommendations from international guidelines, supported by moderate to low-quality from observational studies and meta-analyses. Empiric therapy should utilize broad-spectrum antibiotics to cover Gram-positive, Gram-negative, and anaerobic organisms, tailored to the suspected source, patient risk factors, and local resistance patterns. For example, a combination such as (for Gram-positive coverage, including in high-risk patients) plus piperacillin-tazobactam (for Gram-negative and anaerobic coverage) is commonly recommended as initial therapy in adults with sepsis or . In cases of high risk for multidrug-resistant organisms, two agents active against may be used, though this is a weaker recommendation based on very low-quality evidence. Beta-lactam antibiotics, such as piperacillin-tazobactam, are suggested to be administered via prolonged infusion to optimize and . Once microbiological cultures and clinical response are available, typically within 48-72 hours, therapy should be de-escalated to pathogen-specific narrower-spectrum agents to reduce the selective pressure for resistance and minimize adverse effects. Daily reassessment is strongly recommended over fixed durations, with a moderate quality of evidence supporting improved outcomes from this practice. The overall duration is generally limited to 7-10 days, but shorter courses (e.g., 5 days for uncomplicated urinary tract sources) are preferred when source control is achieved. Antifungal and antiviral agents are added when indicated by risk factors or diagnostics. For suspected invasive candidiasis in high-risk patients, such as those who are immunocompromised or have persistent fever despite broad antibacterial therapy, empiric echinocandins (e.g., caspofungin or micafungin) are recommended as first-line therapy due to their superior efficacy over azoles in critically ill patients. Antivirals, such as oseltamivir for influenza-associated sepsis, should be initiated promptly if a viral etiology is suspected. Antimicrobial stewardship programs play a vital role in sepsis care by promoting appropriate empiric selection based on institutional resistance patterns, ensuring timely de-escalation, and monitoring for overuse. These programs, integrated into guidelines, help mitigate the global rise in multidrug-resistant pathogens while maintaining effective therapy.

Fluid and Hemodynamic Management

Fluid resuscitation is a cornerstone of hemodynamic management in sepsis, aimed at restoring intravascular volume and improving tissue perfusion in patients with sepsis-induced hypoperfusion or . The Surviving Sepsis Campaign (SSC) guidelines recommend administering at least 30 mL/kg of intravenous (IV) crystalloid fluid within the first 3 hours of recognition. Crystalloids are preferred over colloids as the initial fluid of choice due to equivalent efficacy and lower cost, with balanced crystalloids (such as lactated Ringer's) suggested over normal saline to reduce the risk of hyperchloremic and . This preference is supported by the SMART trial, which demonstrated that balanced crystalloids were associated with lower in-hospital mortality and fewer major adverse kidney events in critically ill adults, including those with sepsis. Vasopressor therapy is initiated if persists after adequate fluid resuscitation to maintain () at or above 65 mm Hg, which has been shown to optimize organ without increasing adverse events compared to higher targets. is the first-line vasopressor due to its potent vasoconstrictive effects, lower arrhythmogenic potential, and mortality benefit over alternatives like in . For patients with inadequate on norepinephrine, adding (at low fixed doses of 0.01–0.03 units/min) is suggested as an adjunct rather than escalating the norepinephrine dose, as it may reduce norepinephrine requirements and the incidence of arrhythmias without compromising outcomes. In refractory cases where shock persists despite norepinephrine and , epinephrine may be added or substituted to provide additional inotropic and vasopressor support. Assessing fluid responsiveness is essential to guide further fluid administration and avoid unnecessary volume loading. The SSC guidelines recommend using dynamic indices, such as pulse pressure variation, stroke volume variation, or passive leg raising tests, over static measures like central venous pressure (CVP) or global end-diastolic volume, as dynamic parameters demonstrate superior predictive accuracy for identifying patients who will benefit from additional fluids. A systematic review and meta-analysis confirmed that dynamic assessments reduce mortality and ventilator days in septic patients by enabling more precise resuscitation compared to static parameters. Invasive arterial monitoring is suggested over non-invasive methods when feasible to enhance the reliability of these assessments in hypotensive states. Following initial , a conservative strategy is advised to prevent overload, which can lead to , increased ventilator dependence, and worsened outcomes. This involves restricting additional fluids unless hypoperfusion persists and using diuretics or in fluid-overloaded patients with ongoing , balancing the need for against the risks of iatrogenic harm. In patients with septic shock complicated by cardiac dysfunction and persistent hypoperfusion despite adequate volume and vasopressor support, inotropic agents such as are suggested to improve . is preferred in this context for its beta-adrenergic effects, which enhance without excessive , though evidence for mortality reduction remains limited. Levosimendan is not recommended due to insufficient benefits over standard therapies.

Adjunctive Treatments

Adjunctive treatments in sepsis management encompass supportive therapies aimed at addressing complications and beyond initial , antimicrobials, and hemodynamic support. These interventions are guided by evidence from clinical trials and international guidelines, with recommendations varying in strength based on available data. Corticosteroids, particularly , are suggested for adults with who remain vasopressor-dependent despite adequate fluid . The Surviving Sepsis Campaign (SSC) 2021 guidelines recommend intravenous at a dose of 200 mg per day in such cases, based on weak evidence from randomized controlled trials showing faster resolution of shock and more vasopressor-free days, though without a clear mortality benefit. This approach targets relative , but risks include potential neuromuscular weakness, and its use should be judicious given the low-quality evidence. Blood product transfusions follow a restrictive strategy to minimize risks while supporting oxygen delivery and . For red blood cells, transfusion is recommended when hemoglobin falls below 7 g/dL in most patients, with a strong recommendation supported by moderate-quality evidence from trials demonstrating no mortality difference compared to liberal strategies but reduced transfusion-related complications. The need for red blood cell transfusions often indicates a more significant or prolonged sepsis illness, as anemia worsens with disease severity and duration due to factors such as inflammatory suppression of erythropoiesis and hemodilution; however, transfusions provide supportive care to bridge oxygen delivery until endogenous recovery mechanisms rebound, and many patients achieve full recovery. Platelet transfusions are advised for counts below 10,000/μL in the absence of or for active hemorrhage, particularly in patients with sepsis-associated , to prevent spontaneous without routine prophylactic use in stable cases. Intravenous immunoglobulin (IVIG) is not routinely recommended for sepsis due to low-quality evidence from meta-analyses showing inconsistent mortality reductions after accounting for study biases. However, limited use may be considered in select cases of streptococcal , where expert guidance suggests adjunctive IVIG early in severe illness to neutralize superantigens, though efficacy remains unproven in large trials. Renal replacement therapy (RRT) is indicated for (AKI) in sepsis with life-threatening complications such as severe , , or refractory fluid overload. The SSC 2021 guidelines weakly recommend either continuous or intermittent RRT modalities, with moderate evidence indicating no survival advantage between them, emphasizing individualized selection based on patient . Timing remains controversial, with trials like STARRT-AKI showing no benefit to early (within 8-12 hours of KDIGO 3 AKI) over delayed approaches, potentially increasing dialysis dependence without reducing mortality; thus, deferral is preferred absent urgent indications to avoid unnecessary exposure. Early nutritional support is prioritized to preserve gut barrier function and metabolic in septic patients unable to maintain oral intake. Enteral nutrition is weakly recommended within 72 hours of sepsis onset if the is functional, supported by very low-quality evidence from observational studies and small trials indicating feasibility without harm, though no definitive outcome improvements over delayed feeding. is reserved for cases where enteral routes are contraindicated or poorly tolerated, with guidelines favoring a combined approach to meet caloric needs (25-30 kcal/kg/day) while monitoring for .

Source Control and Surgical Interventions

Source control is a fundamental component of sepsis management, aimed at eliminating the infectious focus, halting ongoing contamination, and restoring premorbid anatomy and function where possible. This involves a range of interventions tailored to the infection site and patient condition, prioritizing the least invasive effective methods to minimize physiological stress. Key principles include draining abscesses or infected fluid collections, debriding necrotic or infected tissue, and removing colonized devices such as central venous catheters or urinary catheters suspected as infection sources. For intravascular devices, prompt removal is recommended once other infection sites are excluded, as retention can perpetuate bacteremia and worsen outcomes. Specific procedures depend on the anatomical location of . drainage under guidance is often first-line for accessible abscesses, such as those in the liver or , avoiding the need for open . In cases of intra-abdominal sepsis like from bowel perforation, is typically required to identify and repair the source, resect necrotic bowel, and perform washout. For complicated by sepsis, surgical interventions such as valve , repair, or replacement are indicated when medical therapy fails or complications like or persistent emboli arise, with early improving in severe cases. These procedures necessitate multidisciplinary input from intensivists, surgeons, and interventional radiologists to optimize execution. Timing of source control is critical, with interventions ideally implemented as soon as medically and logistically feasible after initial and anatomical , targeting completion within 6-12 hours of sepsis recognition. Delays beyond 6 hours from community-acquired sepsis onset are associated with increased 90-day mortality, underscoring the need for rapid escalation. In some scenarios, temporizing measures like percutaneous drainage may bridge to definitive if immediate operation risks hemodynamic instability. Imaging plays a pivotal role in localizing the infection source to guide source control. Computed tomography (CT) with intravenous contrast is the modality of choice for evaluating abdominal, pelvic, or soft tissue infections due to its high sensitivity for abscesses, perforations, and collections. is useful for superficial or vascular sites, such as suspected or endocarditis vegetations, while is reserved for complex cases like spinal infections when CT is inconclusive. These studies should be performed judiciously in unstable patients to avoid delays, focusing on those likely to alter management. Challenges in source control arise particularly in hemodynamically unstable patients, where the risks of and must be balanced against the benefits of elimination. Logistical barriers, such as operating room availability or expertise, can delay interventions, and assessing adequacy of control relies on clinical response and repeat rather than definitive biomarkers. In such cases, a stepwise approach—starting with less invasive options—helps mitigate perioperative risks while addressing the .

Management in Special Populations

In neonates, sepsis management emphasizes prompt empiric with narrower-spectrum agents such as combined with gentamicin to cover common pathogens like group B Streptococcus and , followed by de-escalation based on culture results and sensitivities. Fluid resuscitation is tailored with smaller boluses of 10 to 20 mL/kg of balanced crystalloids, administered over 10 to 20 minutes and repeated up to a total of 40 to 60 mL/kg if needed, to minimize the risk of fluid overload in immature cardiovascular systems. Supportive care includes exogenous administration for preterm infants with respiratory distress complicating sepsis, which improves oxygenation and reduces dependence. For elderly patients, fluid administration requires caution to prevent precipitating , with an initial crystalloid bolus limited to 500 mL or 10 to 15 mL/kg rather than the standard 30 mL/kg, guided by dynamic assessments of such as output and mental status. Vasopressor dosing, typically starting with norepinephrine, is adjusted to lower thresholds—targeting a of 65 mmHg or even 60 to 65 mmHg in those with comorbidities—to balance hemodynamic support while avoiding excessive adrenergic stress on fragile . The 2025 S3 guidelines reinforce this geriatric tailoring by recommending conservative fluid strategies and comorbidity-adjusted vasopressor targets, alongside daily reassessment to account for age-related pharmacokinetic changes. In immunocompromised patients, such as those with cancer or , empiric antimicrobial therapy employs broader coverage, including anti-pseudomonal beta-lactams (e.g., piperacillin-tazobactam or ) plus for methicillin-resistant Staphylococcus aureus risk, with consideration of aminoglycosides for severe cases. Prophylactic antimicrobials, like levofloxacin or , should be continued during sepsis treatment to prevent secondary opportunistic infections, particularly in high-risk scenarios such as prolonged . Source control remains urgent, often necessitating early transfer for multidisciplinary intervention. Management in pregnant women prioritizes maternal stabilization while avoiding teratogenic agents; empiric antibiotics favor pregnancy-safe options like plus gentamicin for chorioamnionitis or plus for , initiated within one hour of sepsis recognition. Continuous fetal monitoring is essential to assess uteroplacental , with delivery deferred unless obstetric indications arise, as sepsis alone does not mandate immediate cesarean section. Source control takes precedence, employing minimally invasive techniques like percutaneous drainage when feasible, integrated with standard sepsis bundles adapted for physiologic changes such as increased plasma volume. The 2025 S3 guidelines extend pediatric tailoring to neonates by endorsing early broad-spectrum antibiotics within one hour for and initial fluid boluses of 20 mL/kg, aligning with international pediatric standards while emphasizing local resistance patterns.

Prognosis and Outcomes

Short-Term Prognosis

The short-term prognosis of sepsis is characterized by significant mortality risk, particularly in its more severe forms. In-hospital mortality for sepsis ranges from 10% to 20%, while is associated with rates of 30% to 50%, depending on the and healthcare setting. These figures vary by source, with pneumonia-related sepsis exhibiting higher mortality, often exceeding 30% due to rapid respiratory compromise and multi-organ involvement. Several predictors influence short-term outcomes in sepsis patients. Advanced age and preexisting comorbidities, such as diabetes or chronic kidney disease, substantially elevate mortality risk by impairing immune response and reserve capacity. Elevated initial lactate levels greater than 4 mmol/L signal tissue hypoperfusion and are independently associated with increased in-hospital death rates, with odds ratios exceeding 2.5 in multiple cohorts. A Sequential Organ Failure Assessment (SOFA) score greater than 6 at presentation indicates severe organ dysfunction and correlates with 28-day mortality rates above 40%. Delayed initiation of antimicrobial therapy further worsens prognosis, with each hour of postponement raising mortality by 7% to 10% in septic shock. Prognostic scoring systems aid in stratifying ICU patients with sepsis. The Acute Physiology and Chronic Health Evaluation II () score, incorporating physiological variables and chronic health status, predicts in-hospital mortality with an area under the curve of approximately 0.80 in septic cohorts. Similarly, the Simplified Acute Physiology Score () evaluates acute illness severity and has demonstrated comparable accuracy for 28-day outcomes, often outperforming simpler tools in heterogeneous ICU populations. Adherence to early sepsis bundles has improved short-term survival, achieving relative mortality reductions of around 20% to 25% through timely and antibiotics. However, as of 2025, high mortality persists in low-resource settings, where over 80% of global sepsis deaths occur, driven by limited access to diagnostics and care, with case fatality rates reaching 50% or more in low- and middle-income countries.

Long-Term Effects

Survivors of sepsis frequently experience post-sepsis syndrome (PSS), a multifaceted condition encompassing physical, cognitive, and psychological impairments that can persist for months or years after the acute episode. PSS affects up to 50% of sepsis survivors and is characterized by symptoms such as chronic fatigue, due to critical illness and , cognitive deficits including memory and attention impairments, and psychiatric issues like (PTSD), anxiety, and depression. A prominent feature of PSS is prolonged immunosuppression, which increases the risk of recurrent infections, including pneumonia, by impairing immune recovery and heightening vulnerability to reinfections. These manifestations arise from the and organ stress during sepsis, leading to long-term disruptions in and daily functioning, with many survivors reporting persistent sleep disturbances and reduced physical endurance. Organ-specific long-term complications further compound the burden of PSS. Sepsis-associated often progresses to acute kidney disease and (CKD), increasing the risk of end-stage renal failure and necessitating ongoing dialysis in severe cases. Similarly, , particularly , develops in a significant proportion of survivors due to inflammatory damage to nerves during the critical phase, resulting in , , and motor deficits that impair mobility and . These effects highlight the need for vigilant monitoring of renal and neurological function in post-discharge care. Readmission rates underscore the ongoing vulnerability of sepsis survivors, with approximately 20-30% requiring readmission within 30 days, often due to recurrent infections, worsening , or complications from PSS. Addressing these risks requires comprehensive rehabilitation strategies, including multidisciplinary follow-up involving for , cognitive behavioral therapy for PTSD, and nutritional support to mitigate frailty. Such programs, delivered through specialized sepsis follow-up clinics, aim to improve functional outcomes and reduce readmissions by tailoring interventions to individual needs. The 2025 update to the German S3 guidelines on sepsis emphasizes structured follow-up care as a core component of long-term management, recommending routine post-discharge assessments to detect and treat PSS early, thereby enhancing survivor recovery and . This shift reflects growing evidence that proactive, multidisciplinary interventions can mitigate the chronic impacts of sepsis and support reintegration into daily activities.

Epidemiology

Incidence and Prevalence

Sepsis imposes a substantial global burden. According to a 2020 report based on 2017 data, there were an estimated 48.9 million cases and 11 million associated deaths, accounting for nearly 20% of all global deaths. However, more recent estimates from the published in October 2025 indicate 166 million cases (95% uncertainty interval 135–201 million) and 21.4 million sepsis-related deaths (20.3–22.5 million) in 2021, representing 31.5% of all global deaths and reflecting a surge partly attributable to the . This burden is disproportionately higher in low- and middle-income countries. In the United States, sepsis affects at least 1.7 million adults each year, resulting in approximately 350,000 deaths either during hospitalization or within 30 days afterward. Incidence rates have shown an upward trend, driven by aging populations, rising , and shifts in healthcare delivery. The COVID-19 pandemic triggered a notable surge in cases from 2020 to 2022, with global sepsis-related deaths increasing substantially compared to pre-pandemic levels (from 14.1 million in 2019 to 21.4 million in 2021), partly due to heightened vulnerability in hospitalized patients. Demographically, sepsis exhibits a bimodal age distribution, with elevated incidence among infants and the elderly; for instance, individuals aged 70 years and older have experienced a 230% rise in incidence since 1990. There is also a slight predominance, with males comprising about 52.5% of cases and consistently higher mortality rates across age groups compared to females.

Risk Factors and Disparities

Sepsis risk is influenced by both non-modifiable and modifiable factors, with significant disparities exacerbating outcomes across populations. Non-modifiable risk factors include advanced age, certain ethnic backgrounds, and chronic health conditions. For instance, older adults face heightened vulnerability due to and , contributing to higher incidence rates. Black and Hispanic individuals experience elevated sepsis incidence and mortality compared to populations, with studies showing nearly double the rates in these groups, often linked to underlying socioeconomic and biological factors. Rural residency further compounds risks through limited access to timely care, resulting in higher in-hospital mortality for sepsis patients in rural versus urban settings. Modifiable risk factors offer opportunities for prevention through lifestyle and behavioral changes. substantially increases sepsis incidence by impairing immune function and promoting chronic disease, a common entry point for infections. practices elevate infection risks, particularly in healthcare and community settings, while delayed or missed vaccinations against preventable diseases like or pneumococcus heighten susceptibility to sepsis-triggering infections. Healthcare disparities perpetuate unequal sepsis burdens, with lower survival rates in underserved areas stemming from delayed and treatment. Patients in low-resource regions often face barriers such as limited hospital access and inadequate emergency services, leading to worse outcomes. The COVID-19 pandemic amplified these risks, as unvaccinated individuals showed markedly higher rates of severe infections progressing to sepsis. Globally, sepsis disproportionately affects low- and middle-income countries, where the majority (over 80%) of sepsis-related deaths occur, driven by infectious disease prevalence, poor , and constrained healthcare ; 2021 estimates indicate 21.4 million such deaths worldwide, with the highest rates in regions like . These inequities highlight the need for targeted interventions to address both individual risks and systemic barriers.

History

Early Recognition

The concept of sepsis traces its origins to ancient Greece, where Hippocrates in the 5th century BCE first described it using the term "sepsis," derived from the Greek word meaning "to rot" or "putrefaction." He associated this process with the decomposition of tissues leading to fever, corruption of the blood, and systemic illness, viewing it as a natural outcome of bodily imbalance rather than supernatural causes. Hippocrates' observations in works like the Corpus Hippocraticum emphasized clinical signs such as fever and putrid discharges as indicators of this decaying state, laying foundational principles for recognizing infection-related deterioration. In the , the understanding of sepsis advanced with the recognition of "blood poisoning," a term commonly used to describe the systemic spread of infection through the bloodstream, often resulting in high mortality. This era saw pivotal contributions from and , who through their germ theory experiments linked specific microorganisms to infectious diseases, including those causing blood poisoning or septicemia. For instance, Koch isolated responsible for septicemia in 1878, providing microbiological evidence that sepsis arose from microbial invasion rather than mere . Earlier, in 1847, demonstrated the preventable nature of puerperal sepsis—a severe form of blood poisoning in postpartum women—by instituting handwashing with chlorinated lime solutions in Vienna's maternity wards, dramatically reducing mortality rates from over 10% to under 2%. His work highlighted the role of contaminated hands in transmitting infection, though it faced initial resistance from the medical community. By the early , clinicians began to recognize shock as a critical manifestation of severe infections, particularly in the context of wound-related sepsis observed during . Military surgeons noted that infected wounds often led to a profound hypotensive state, termed "," characterized by circulatory collapse and organ failure beyond simple blood loss. This period marked the initial distinction of sepsis-induced shock from traumatic or hypovolemic forms, prompting early investigations into fluid resuscitation and supportive care, though effective treatments remained limited until later advances.

Key Developments and Milestones

In the 1970s, foundational advances in understanding sepsis pathophysiology laid the groundwork for later diagnostic frameworks, including the development of the assay in 1970 to detect endotoxins in patients with gram-negative bacteremia, which helped link bacterial components to systemic responses. Additionally, the identification of alpha (TNF-α) in 1975 as a central mediator in highlighted the role of cytokines in driving inflammatory cascades. These discoveries shifted focus from purely infectious causes to dysregulated host responses, influencing subsequent conceptualizations. The (SIRS) criteria emerged in the early 1990s as a pivotal milestone, formalized at the 1992 American College of Chest Physicians (ACCP) and Society of Critical Care Medicine (SCCM) consensus conference, which defined sepsis as plus two or more SIRS criteria—such as abnormal temperature, , , or white blood cell count—while distinguishing severe sepsis (with ) and (with refractory ). This framework standardized identification and enabled clinical trials, though it was later critiqued for lacking specificity to . A major therapeutic breakthrough occurred in 2001 with the publication of the Early Goal-Directed Therapy (EGDT) protocol by Emanuel Rivers and colleagues, a demonstrating that protocolized targeting central venous , , and lactate clearance within the first six hours reduced mortality from 46.5% to 30.5% in severe sepsis and patients in the . EGDT emphasized rapid fluid , vasopressors, and inotropes, becoming a cornerstone of the Surviving Sepsis Campaign's initial guidelines and influencing global standards for timely intervention. The 2016 Sepsis-3 task force, convened by the SCCM and European Society of Intensive Care Medicine, redefined sepsis as life-threatening caused by a dysregulated host response to , using a Sequential Organ Failure Assessment ( increase of 2 or more points, and as persistent requiring vasopressors with lactate above 2 mmol/L despite fluid . This shift de-emphasized SIRS in favor of metrics, improving diagnostic precision and alignment with outcomes data from large cohorts. Guideline updates continued to evolve management practices; the 2021 Surviving Sepsis Campaign international guidelines, developed by SCCM and ESICM, incorporated evidence from over 100 studies to recommend hourly screening, broad-spectrum antimicrobials within 1 hour, and corticosteroids for vasopressor-refractory , while endorsing dynamic over static fluid targets to minimize overload. In 2025, the German S3 guidelines on sepsis underwent revisions, introducing 29 new and 16 updated recommendations focused on prevention strategies, such as vaccination and hygiene protocols, alongside enhanced follow-up care for long-term sequelae like post-sepsis syndrome, while retaining 43 core elements from prior versions.

Societal Impact

Economic Burden

Sepsis imposes a substantial economic burden on healthcare systems worldwide, with direct medical costs in the United States estimated at more than $53 billion annually for in-hospital care. This figure positions sepsis as a leading cause of hospitalization costs in the U.S., driven by prolonged (ICU) stays and resource-intensive treatments. The average cost per sepsis hospitalization was approximately $28,800 in 2021, reflecting extended hospital lengths of stay averaging 9.2 days and high utilization of critical care services. Indirect costs further amplify the financial impact, encompassing lost from illness, long-term among survivors, and premature mortality. Early estimates suggested these non-medical expenses accounted for a significant portion of the total economic burden of severe sepsis. In the U.S., such contribute significantly to the overall tally, exacerbating societal economic strain beyond immediate healthcare expenditures. A 2025 systematic review indicated that long-term costs after sepsis, including readmissions, can exceed $60,000 per patient in the first year in high-income settings. Globally, the economic burden is disproportionately higher in low- and middle-income countries (LMICs), where limited healthcare amplifies costs relative to available resources. While direct treatment costs in LMICs are generally lower than in high-income settings—often due to less advanced care options—these expenses still consume a large share of constrained budgets, with like lost productivity representing an even greater proportion amid widespread and inadequate support systems. Recent studies report mean hospital costs per sepsis ranging from $222 in lower-middle-income countries to $13,845 in high-income countries. Early intervention through sepsis care bundles has demonstrated cost-effectiveness by reducing mortality and lengths of stay, potentially saving thousands of dollars per patient. of these bundles, such as standardized protocols for timely antibiotics and fluid resuscitation, has been associated with net cost reductions in multiple studies, including one statewide program that achieved dominance in cost-effectiveness by lowering both expenses and death rates. Post-COVID-19 trends have intensified the burden, with sepsis-related hospitalizations in the U.S. rising by 39% from 1.8 million in 2016 to 2.5 million in 2021, leading to elevated costs and resource demands that persist into 2025. Projections for 2025 incorporate these increases, estimating sustained or higher annual expenditures amid ongoing sequelae from viral infections and strained healthcare capacities.

Education and Awareness

Education for healthcare providers emphasizes simulation-based training to enhance recognition and of sepsis, which has been shown to improve , skills, and in handling septic patients. High-fidelity simulations, including interprofessional scenarios, are integrated into training programs to replicate real-world challenges and promote adherence to evidence-based protocols. Sepsis protocols, aligned with guidelines like those from the Surviving Sepsis Campaign, are routinely incorporated into medical and curricula to foster early identification and timely intervention. Public awareness campaigns play a crucial role in disseminating information about sepsis symptoms and the need for prompt medical attention. The World Sepsis Day, initiated in 2010 by the Global Sepsis Alliance and supported by the , is observed annually on to raise global awareness through events, resources, and advocacy efforts. In the United States, the Sepsis Alliance leads initiatives such as Sepsis Awareness Month in September and public service announcements to educate communities on prevention and early signs of sepsis. Key barriers to effective sepsis and include under-recognition of symptoms among both providers and the , which delays treatment and worsens outcomes. In low- and middle-income countries (LMICs), additional challenges arise from limited resources, low , and cultural stigma surrounding infections, which can hinder timely seeking of care and perpetuate inequities. These campaigns have demonstrated measurable impacts, with awareness efforts leading to significant improvements in early reporting and recognition; for instance, initiatives have been associated with reductions in mortality risk through better compliance and timely presentation. The 2025 update of the S3 guidelines on sepsis prevention, , , and follow-up care, adapted from the Surviving Sepsis Campaign, further supports integration into by providing updated recommendations for training programs worldwide.

Research Directions

Current Advances

The 2025 update to the S3 guidelines on sepsis prevention, , treatment, and follow-up care introduced 29 new recommendations, with a strong emphasis on diagnostics such as enhanced utilization for early detection and screening to improve timeliness of intervention. Additionally, 16 recommendations on were revised, including refinements to fluid resuscitation strategies to optimize hemodynamic support while minimizing risks like overload in heterogeneous patient populations. These updates, building on prior international frameworks, underscore a shift toward more individualized and evidence-based approaches, with 43 recommendations remaining unchanged to maintain continuity in core practices. Advances in precision medicine have leveraged to enable risk stratification in sepsis, identifying transcriptomic endotypes that classify patients into subgroups with distinct immune dysregulation profiles. For instance, gene expression-based clustering from large cohorts has delineated four consensus endotypes associated with varying mortality risks, such as immunosuppressive profiles (e.g., SRS1) linked to higher 28-day mortality rates of around 22% compared to 10% in adaptive immune states (SRS2). Polygenic risk scores derived from genomic variants have further enhanced predictive models, improving in specific populations by integrating with clinical data to guide personalized prognostic and therapeutic decisions. These genomic tools facilitate subphenotyping, allowing for targeted interventions like immunomodulators in high-risk strata. Artificial intelligence and machine learning models have transformed early sepsis detection by analyzing electronic health records (EHRs), achieving high predictive accuracy up to 6-24 hours before clinical onset. For example, deep learning algorithms processing vital signs, lab results, and temporal patterns in EHR data have demonstrated AUROC values exceeding 0.85 in validation cohorts, enabling real-time alerts in hospital settings. A notable milestone is the FDA authorization in of the Sepsis ImmunoScore, an AI tool that stratifies at-risk patients using routine data, reducing detection delays and supporting bundle compliance in diverse ICUs. These systems prioritize interpretability, with explainable AI features highlighting key contributors like lactate trends to aid decision-making. Insights from the have illuminated viral sepsis phenotypes, revealing distinct immune signatures that differentiate pure viral from mixed viral-bacterial presentations in critically ill patients. Studies identified phenotypes characterized by profound lymphopenia and in viral sepsis, contrasting with hyperinflammatory bacterial profiles, which informed subtyping models with prognostic implications such as elevated mortality in mixed cases (up to 40% higher odds). Transcriptomic analyses further highlighted pathway differences, like reduced T-cell responses in viral-dominant sepsis, guiding adjunctive therapies and strategies during outbreaks. These findings have refined sepsis definitions to incorporate viral triggers, enhancing overall phenotyping frameworks. Vaccine developments targeting common sepsis pathogens, particularly pneumococcal strains, have advanced prevention efforts through higher-valency conjugates offering broader coverage. The FDA approval of PCV21 (Capvaxive) in 2024 extends protection against 21 s, building on PCV20 (Prevnar 20) from 2021, and has demonstrated strong in adults against serotypes responsible for approximately 84% of invasive pneumococcal cases in recent data, with modeling suggesting substantial reductions in IPD incidence and related hospitalizations. These target high-risk groups, including the elderly and immunocompromised, with post-marketing data confirming sustained efficacy against sepsis-causing strains like 3. Ongoing into protein-based universal pneumococcal aims to address non-vaccine serotypes, potentially further mitigating sepsis burden.

Emerging Therapies and Prevention

Recent research has highlighted the potential of immunomodulatory therapies to address the dysregulated immune response in sepsis. Anti-cytokine drugs, such as interleukin-6 inhibitors, aim to mitigate the cytokine storm by targeting excessive inflammation, with preclinical studies showing reduced organ damage in animal models. Mesenchymal stem cells (MSCs) represent another promising avenue, exhibiting anti-inflammatory and immunomodulatory effects through paracrine signaling that modulates immune cell activity and promotes tissue repair. Clinical trials, including a phase 1 dose-escalation study in septic shock patients, have demonstrated safety and preliminary efficacy in lowering systemic cytokine levels with MSC infusions at doses around 1 × 10^6 cells/kg. Ongoing trials in 2025 continue to explore MSC combinations with antibiotics, reporting improved survival in sepsis models by ameliorating organ dysfunction. Prevention strategies emphasize infection control to avert sepsis onset, particularly in high-risk settings. Hand hygiene protocols, including the use of alcohol-based sanitizers and , remain foundational, with evidence from showing reductions in healthcare-associated infections that precede sepsis. Vaccine programs targeting common bacterial pathogens, such as pneumococcal and meningococcal vaccines, contribute to community-level prevention by decreasing invasive infections in vulnerable populations like the elderly and immunocompromised. In surgical contexts, sepsis bundles—standardized protocols incorporating timely antibiotics, fluid resuscitation, and source control within one hour of recognition—have been implemented to lower postoperative sepsis rates, with studies in 2024 reporting improved survival outcomes post-adoption. Biomarker-guided therapy is advancing personalized antibiotic management in sepsis by enabling tailored durations and selections based on host response. (PCT) and (CRP) levels guide de-escalation, with recent meta-analyses indicating that PCT-directed protocols shorten courses by 2-3 days without compromising outcomes, potentially reducing resistance risks. A 2025 multicenter trial confirmed that combining PCT with CRP enhances diagnostic accuracy for bacterial sepsis, supporting stewardship in intensive care units. Despite these advances, sepsis trials face significant challenges, exemplified by the failure of recombinant activated (drotrecogin alfa), which initially showed mortality benefits in early studies but failed to replicate them in larger phase 3 trials, leading to its withdrawal in 2011 due to lack of efficacy and bleeding risks. Heterogeneity in patient populations, timing of interventions, and endpoint definitions continue to hinder success, underscoring the need for better preclinical models. The 2025 update to the S3 guidelines introduces a stronger emphasis on post-sepsis care, recommending multidisciplinary follow-up to address long-term sequelae like and physical debility through rehabilitation programs. Community prevention efforts are also prioritized, advocating for public education on early recognition and social risk factor mitigation to reduce incidence in underserved areas.

References

Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.